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1 ABSTRACT 
Bendamustin is an alkylating anticancer agent which is currently in routine use for the 
treatment of different types of cancer. The drug is very unstable in serum due to hydrolysis; 
the half life of the first part of the serum elimination curve is about 6-10 minutes. The rapid 
degradation of the drug in serum impairs its cytostatic action within a short period of time, 
and frequent application of relatively high doses is required. This, in turn, leads to dose-
limiting systemic toxicity. Incorporation of bendamustin into liposomes might be a promising 
way to prolong its half life in plasma, and thus improve the efficiency and toxicity profile of 
the drug. Up to now only a few attempts to incorporate bendamustin into liposomes are found 
in literature. However, none of these have been successful and reached clinical practice. 
Recently, a new technique for liposome preparation, dual asymmetric centrifugation (DAC), 
has been suggested which is suitable for making liposomes immidiatly prior to application 
(bed-side preparation). In a previous study a protocol for liposomes made of phosphatidyl 
choline and cholesterol was developed and used for direct entrapment of bendamustin. 
However, the formulation turned out to be unstable in terms of rapid efflux of bendamustin 
out of the liposomes. 
 
In this study, a new liposomal formulation of bendamustin was developed using the DAC. 
The intention was to improve the stability of the liposome formulation by obtaining a reduced 
leakage of drug. Liposome release of incorporated drug was investigated by incubation of 
liposomes under physiological conditions; 37 °C, with further assay of the samples with 
respect to loss of incorporated drug over time. For this, cation-exchange chromatography and 
RP-HPLC was used. It turned out that bendamustin in its zwitterionic form tended to diffuse 
through the lipid-membrane more readily than both the cationic and anionic forms. In order to 
reduce the amount of zwitterionic molecules, and hence efflux, a buffered system with a pH 
of 2.0 in the liposome interior was chosen. Compared to the previous formulation, the new 
formulation showed an increase in encapsulation efficiency as well as a slower efflux of drug 
when incubated in phosphate buffered saline pH 7.4 at 37 ºC; EE= 61% ± 2 as compared to 44 
% ± 3 and t1/2= 3 h as compared to 1.5 h.  
 
Stability of the new formulation was assayed with respect to intact bendamustin as well as 
lipid at 23 °C over 24 hours. For this RP-HPLC and HPTLC were used, respectively. The 
results showed that the formulation is stable enough to be used within the same day as a bed-
side preparation. Furthermore, stability of the new bendamustin-liposomes was compared to 
the free drug in cell culture medium at 37 ºC. Unfortunately, the bendamustin-liposomes 
showed a minor improvement in stability as compared to the free bendamustin only; the half 
life was prolonged to 20 minutes for the liposomes (14 minutes for the solution). Finally, an 
attempt of active loading of bendamustin was performed by the means of a pH gradient 
between the liposome interior and exterior. An EE of 14 % was observed. Further 





CH  Cholesterol  
EE  Encapsulation efficiency  
EPC3  Hydrogenated egg phosphatidyl choline 
EPC3/CH Mixture of hydrogenated egg phosphatidyl choline and cholesterol 
HPLC  High performance liquid chromatography 
i.v  Intravenous 
LUV  Large unilamellar vesicle 
MLV  multilamellar vesicle 
m/m  Mass ratio 
Mw  Molecular weight 
PBS  Phosphate buffered saline 
PC  Phosphatidyl choline 
PCS  Photon correlation spectroscopy 
P.I.  Polydispersity index 
RES  Reticulo endothelial system 
RP-HPLC Reversed phase high performance liquid chromatography 
SD  Standard deviation 
SUV  Small unilamellar vesicle 
t ½  Half- life 
VPG  Vesicular phospholipid gel 







Cancer is the uncontrolled growth and spread of cells that may affect almost every tissue of 
the body. Normally proliferation and apoptosis of body cells is a strictly controlled process. A 
normal cell turns into a cancer cell because of one or more mutations in its DNA, which the 
body is not able to repair. Instead of apoptosis, the cells outlive normal cells and continue to 
grow and divide to form new abnormal cells. The cancer cells might spread by the blood- 
stream to other parts of the body where they begin to grow and replace normal tissue. This 
process is called metastasis [1]. 
 
Cancer is a disease that is affecting us all. More than 11 million people worldwide are 
diagnosed with cancer every year [2]. According to the Cancer registry in Norway, 24 228 
new cases of cancer was detected in 2005. Of these 12706 were males and 11522 females. 
One third of every Norwegian will get cancer in the course of life [3]. The frequency of 
different types of cancer is dependent on different factors as sex and age. Overall, prostate 
cancer is the most common cancer type among males, and breast cancer among women [3]. 
 
The incidence of cancer in Norway has increased drasticaly the last decades (figure 1). 
Fortunately, today more than half of those who get a diagnose, survive cancer. The current 
therapy for cancer is based predominantly in surgical removal of tumours, radiotherapy and 
chemotherapy with antineoplastic drugs. A lot of research is carried out, with the intention to 
improve the efficacy of the treatment. Some of the goals are to make the antineoplastic drugs 









Figure 1: Age adjusted incidence rate, all cancer types combined, 1953-2004. Figure taken 




Chemotherapy is often only possible treatment in non solid tumours and metastases spread in 
the body [4]. Cytotoxic drugs apply to any drug that inhibit cell division and are potentially 
useful in cancer chemotherapy. The main cytotoxic drugs can be divided into the following 
categories [1]: 
 
- Alkylating agents, which act by forming covalent bonds with DNA and thus impeding 
DNA replication. 
- Antimetabolites, which block or subvert one or more of the metabolic pathways 
involved in DNA synthesis. 






3.2 Alkylating agents  
 
Alkylating agents are developed from mustard gas (dichlorethylsulfid) which was used as the 
first time during the 1st world war as a war fare agent. The gas was yellow-brown in colour 
and had an odour resembling mustard, which is how it got its name. Mustard gas was the most 
lethal of all poisonous chemicals used during the war. To day sulphur mustard is regulated 
under the 1993 Chemical Weapons Convention [5]. 
 
Despite the tragic history, mustard gas was the beginning of the modern era of cancer 
chemotherapy. After the war, two pharmacologists, Louis S. Goodman and Alfred Gilman, 
observed that people exposed to mustard gas had revealed profound lymphoid and myeloid 
suppression. They reasoned that this agent could be used to treat lymphoma, since lymphoma 
is a tumour of lymphoid cells. After injection of less toxic nitrogen mustard into a patient with 
non-Hodkin`s lymphoma, a dramatic reduction in the patient`s tumor masses was observed. 
This was the first step to the realization that cancer could be treated by pharmacological 
agents [6]. 
 
Modifications of the dichlorethylsulfid- molecule have been made in order to reduce its 
reactivity and toxicity, resulting in alkylating cytostatics used in chemotherapy. The sulfid has 
been exchanged with less reactive nitrogen, and different alkyl groups and aromatics have 
been added in order to withdraw electrons away from nitrogen, thus making it less reactive 
and toxic to normal tissue. (figure 2 and 3) 
    
Figure 2: Sulfur mustard    Figure 3: Nitrogen mustard 
 
Alkylating agents contain chemical groups that can form covalent bonds with particular 
nucleophilic substances in the cell, and thus impeding DNA replication. Most alkylating 
agents have two alkylating groups and can cross-link two nucleophilic groups and cause intra 
or interchain cross-linking. This interfere transcription as well as replication. The resulting 
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Figure 4: Mechanism of action alkylating agents, where one of the two alkylating groups 




Bendamustin is an alkylating cytostatic drug which was developed in the early 1960s at the 
Microbiological and Experimental Therapy group in Jena, Germany. The idea was to combine 
a purine and amino acid antagonist with an alkylating nitrogen mustard group; bifunctional 












The chemical name of the active ingredient Bendamustinhydrochloride: 




C16H18Cl2N3O2 × HCl 
 
Molecular weight: 394.7 g/mol 
 
Calculated pKa values [9]; 
4.5 ± 0.10 (most acidic, 25 °C) 
















Figure 5: Structural formula of bendamustinhydrochloride. 
 
Mechanism of action 
Bendamustin is a bifunctional alkylating agent with antineoplastic and cytocidal properties. 
The efficacy is attributed mainly to crosslinking of the DNA single and double strands by 
alkylation. It is not yet known whether the benzimidazole ring possesses additional 




Today bendamustin is marketed under the name Ribomustin®. 
Ribomustin® is registered as single- agent therapy or in combination with other antineoplastic 
drugs for the treatment of the following malignancies [13]: 
 
- Breast cancer 
- Hodkin`s disease 
- Non-Hodkin`s lymphoma 
- Plasmocytoma 
- Chronic lymphocytic leukaemia 
 
Stability and pharmacokinetics 
Bendamustin is very unstable in water due to hydrolysis into monohydroxy- and dihydroxy- 
bendamustin [14]. The drug is available as a freeze- dried powder. Bendamustin- solution is 
administered intravenously using 0.9 % sodium chloride solution as a diluent. The presence of 
sodium chloride in the infusion is slowing down the hydrolysis of the drug. (Stability in 0.9 % 
sodium chloride 0.25 mg/ml; 4 ºC t90= 120 h, 23 ºC t90= 9 h [15]). The reason for the 
increased stability in sodium chloride solution is most probably due to the presence of 
chloride ions working as competitative inhibitors for the nucleophilic H2O molecules, and 
hence reducing degradation of the chlorine bounds of the molecule.  Hydrolysis and stability 
of bendamustin is pH dependent. Hydrolytic cleavage of the chlorine bonds is fast at pH 
values above 6 [14]. Bendamustin is a zwitterionic molecule with two pKa values: 4.6 and 
6.3. Low pH will give rise to a protonation of the carboxylic group and the amino-group(s), 
whilst a high pH results in deprotonation.  
 
In serum bendamustin is bound to plasma proteins, mainly albumin, to the extent of 95 
%.[16], [17], [18]. The distribution volume is 15.8-20.5 L at steady state. The drug is 
extremely unstable in serum, due to hydrolysis. Following bolus injection, the plasma level 
follows a biphasic exponential pattern. The elimination half life of the alfa phase is between 6 
and 10 minutes, and the terminal half life (beta phase) between 28 and 36 minutes. The 
substance is primarily metabolised in the liver and eliminated by the kidneys [17], [18]. 
 
Entrapment of drug within liposomes is a way to protect the drug from its systemic 
environment. Some advantages with liposomes as drug formulations are their ability to 
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prolong half-life of unstable drugs in serum and thus improve its activity toward cancer cells. 
Liposomal entrapment of the bendamustin might be a way to reduce hydrolysis of the drug in 
serum, and hence prolong its half life. 
3.4 Liposomes 
 
Liposomes are spherical vesicles which enclose an aqueous core by a membrane composed of 
lipid molecules, usually phospholipids. Liposomes are spontaneously formed when lipids are 
dispersed in aqueous solution by mechanical energy. The vesicles formed may consist of one 
or more concentric bilayers (lamellae), and have a size range from tens of nanometers to tens 
of micrometers. The composition of an aqueous core as well as a lipid membrane gives the 





Figure 6: Liposome representing incorporation and encapsulation of lipophilic and 
hydrophilic drugs. Figure is taken with permission from Elsvier publisher. 
 
The choice of lipids for liposomal drug carriers is related to the desired stability of the 
liposome formulation, and the drug to be loaded into the liposomes. The most common 
phospholipid used in liposomal drug carriers is phosphatidylcholine (PC). For recent review 
see [20]. PC can be derived synthetically or from natural sources as egg and soya. PC is an 
amphiphilic molecule in which a glycerol bridge links a pair of hydrophobic alkyl 
hydrocarbon chains with a hydrophilic polar headgroup phosphorylcholine [19]. These 
molecules are not soluble in water, but instead of solutions they form colloidal dispersions. 
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The hydrophilic part tends to be in contact with water, whilst the hydrophobic hydrocarbon 
chains prefer to be shielded against water in the interior of the structures. In aqueous media, 
under the influence of mechanical agitation these lipid bilayers are forming closed sealed 
vesicles; liposomes [21]. 
  
Figure 7: Structural formula of phosphatidyl choline 
            
Liposomal membranes can exist in different physical phases depending on the transition 
temperature of the membrane. Transition temperature is a given temperature where the lipid 
membrane goes over from a rigid to a more flexible state which is more permeable. The 
length and degree of saturation of the alkyl chains mainly determines the transition 
temperature of the membrane. For recent review see [20]. Egg PC has a phase transition 
temperature between -15 and -7 ºC, i.e. is in the “fluid”-state at ambient temperature [19]. 
 
Usually when drugs are incorporated into liposomes one wants to prevent leaking and 
premature loss of drug through the membrane. Hydrophilic compounds with a low Mw are 
most prone to leak out of the liposomes due to the concentration gradient between the inside 
and the outside of the liposomes. A normal way of preventing leakage by making the 
membrane more rigid is the use of cholesterol (CH).  CH is a flat, rigid molecule which is 
added to the lipid in order to make a tighter packing of the membrane, and hence 
loss of entrapped drug is reduced. CH can be incorporated in very high mixing ratios, up to a 





Figure 8: Structural formula of cholesterol 
 
Phosphatidylcholine and cholesterol are both very important components in most natural 
membranes. The ability of liposomes to mimic the behaviour of natural membranes, and also 
to be degraded by the same pathways, makes them a very safe and efficacious vehicle for 
medical applications. For recent review see [19].   
 
Classification of liposomes 
Liposomes are often classified according to their size. This is partly because different sizes 
are manufactured in different ways, and partly because different applications demand particle 
sizes in a certain size-range [19].  
 
 Usually, liposomes belong to one of the following categories [19]; 
 Multilamellar vesicles (MLVs): Usually consist of a polydisperse population of 
vesicles covering a size range of 100-1000 nm. The vesicles contain several up to 
hundreds of concentric lamellae. (Vesicles containing just a few concentric lamellae 
are sometimes called oligo-lamellar liposomes.) 
 
 Large unilamellar vesicles (LUVs): These vesicles have a size above 100 nm, and 
normally consist of one concentric lamella. 
 
 Small unilamellar vesicles (SUVs): These are defined as the smallest phospholipids 
vesicles possible. Their size is below 100 nm, and they consist most often of one 







Figure 9: Size, size-distribution and lamellarity of liposomes.  
 
Stability of liposomes 
During storage, physical stability might alter the particle size of liposomes. Aggregation and 
fusion are two unfavourable processes in this respect. Fusion is the occasion when vesicles 
fuse together and make bigger liposomes. Aggregation is the phenomenon where liposomes 
are forming aggregates oftenly accompagnied by sedimentation or flotation, but is on the 
contrary to fusion a reversible process which can be resolved by agitation or stirring [20]. 
 
Two other unfavourable processes regarding stability of liposomes are oxidation and 
hydrolysis of lipids. The resulting chemical degradation of the phospholipids leads to short-
chain phospholipids and lyso-derivatives in the membrane, respectively. Hydrolytic cleavage 
of the ester linkage of PC results in lyso-phophatidylcholine (Lyso-PC). The consequences of 
such reactions might be increased permeability of the bilayers as well as fusion or 
aggregation. Different precautions can be taken to prevent chemical degradation. In the case 
of oxidation, choice of phospholipid, optimal temperature for storage and absence of light and 
oxygen are of importance. The main defence against hydrolysis is selection of optimal pH, 
buffer and lyophilized lipids if possible [22]. 
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It is not much known to which impact presence of Lyso-PC arising from hydrolysis has on 
safety in vivo. However, all biological membranes contain small amounts of lyso-PC as a 
consequence of natural membrane turnover [23]. 
 
 
Figure 10:  Structural formula of Lyso-phosphatidylcholine. 
3.5 Vesicular phospholipid gels 
 
As the name is insinuating, vesicular phospholipid gels are gels formed by phospholipids-
vesicles (VPG). The dispersion does not contain any gelifying agents. It must neither be 
confused with the term “gel-phase” used for phospholipid bilayer systems below their 
transition temperature. VPGs have simply got its name because of its gel-like rehological 
behaviour, deriving from phospholipids vesicles which are so tightly packed that a steric 
interaction between them occurs. Their consistence can be described as viscous to semi-solid, 
with a highly ordered homogenous appearance [24]. 
  
VPGs differ from conventional liposomes in that they contain very high lipid concentrations. 
Like liposomes, VPGs can be made of a single phospholipid, mainly phosphatidyl choline, or 
a mixture of two or more lipids that upon minimal amounts of water swell and form vesicles 
when subjected to mechanical agitation. The vesicles formed are densely packed and appear 
uniform and small in size (mostly unilamellar) [25]. 
 
Because of the consistence of the VPG and the steric interaction between the vesicles, the 
aqueous volume inside and outside the vesicles are the same. This results in no concentration 
gradient between the aqueous core and the water phase surrounding the vesicles. When 
conventional liposomes are stored and uncaptured drug are removed from the dispersion, 
entrapped drug tends to leak out of the liposomes. Since there is no concentration gradient in 
VPGs, as long they are not diluted, such leakage is prevented, and the vesicles do retain a 






Figure 11: Vesicular phospholipids gels reveal the same aqueous volume inside and outside 
the vesicles resulting in no concentration gradient for the incorporated drug. 
 
Another advantage with VPGs is their ability to entrap higher percentages of drug than 
conventional liposomes. This is due to a greater lipid content which results in more liposomes 
per unit volume, and hence an increased ratio of the aqueous part entrapped into liposomes 
compared to the total volume. The vesicles can be loaded with hydrophilic, amphiphilic and 
lipophilic drugs in different ways [24]. The most common technique for preparing VPGs of 
small and uniform vesicle sizes is high- pressure homogenisation. VPGs can be transferred 
into conventional small-sized liposome dispersions by addition of excess aqueous medium 
and gentle mechanical agitation shortly before use [25]. 
3.6 Liposomes in anticancer therapy 
 
Liposomes in cancer therapeutic are maybe the most important, but also one of the most 
complex fields of liposome applications. The main motive for developing liposomes as new 
drug delivery systems was the rather unspecific action of all known antineoplastic drugs 
against tumour cells, giving a low ratio of therapeutic to toxic effects [4]. The intention with 
liposomes as drug delivery formulations is that they should circulate in blood reaching 
specific targets, as sites of inflammations and solid tumors. Normal cells will hence be less 
affected, resulting in a reduction in toxicity and side effects. Up to now intravenous 
administration is the most promising route for liposomal formulations in anticancer therapy 
[4]. 
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The role of liposome size in anticancer therapy 
The size, size-distribution and lamellarity of liposomes play an important role in their use as 
drug delivery formulations, not least in anticancer therapy. 
 
MLVs are the largest type of liposomes although their entrapped volume and hence the ability 
to entrap drug is not necessarily biggest. Once they are infused they are rapidly recognized by 
the immune system and taken up by macrophages which remove them from the circulation. 
Liposomes of intermediate size (LUVs) have a better chance of escaping the reticulo-
endothelial system (RES), and hence have the ability to stay in the circulation for a longer 
period of time. The small liposomes (SUVs) show the shortest circulation time in blood due to 
capillary extravasations.  However, this gives them the opportunity to reach targets outside the 
vasculature such as solid tumors. For recent review see [20]. 
 
The accumulation of SUVs into solid tumours is based on dissimilarities of healthy and 
cancerous tissues; Solid tumours are dependent on higher vascular blood supply than normal 
tissue, because of the high turnover of cells. At the same time, the endothelial walls of blood 
vessels in tumours are more permeable than normal endothelial linings because of an 
increased number of big gaps. This gives SUVs, as for all nanoparticles, the ability to 
penetrate into solid tumours, but not healthy tissues. At the same time the liposomes stay 
longer in the tumour due to reduced lymphatic drainage in tumour tissue [20]. This 
phenomenon is called enhanced permeability and retention effect of liposomes in solid 
tumour tissue. (Figure 12) 
 
Figure 12: The enhanced permeability and retention effect of liposomes in solid tumour 
tissue. Figure is taken with permission from Elsvier publisher. 
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3.7 Challenges with bendamustin-liposomes  
 
Alkylating agents have seldom been used in liposomal formulations. Water soluble alkylating 
agents did not show any improvement in therapeutic effects, and sometimes the drug stability 
was decreased [4]. In a previous study by Fichtner I et al, different alkylating agents, 
including bendamustin, were encapsulated into liposomes in order to investigate toxicity, 
stability and effect of the liposomal formulations compared to the free drugs. The conclusion 
was that only certain lipophilic alkylating drugs were suitable in liposomal formulations. 
Encapsulation of bendamustin did not show any advantages because of its instability in water 
[26]. Whether this is an effect of insufficient encapsulation and/or stability of the liposomes 
used remains unclear. From the stability data in literature it is obvious, however, that aqueous 
bendamustin- preparations are not suitable for storage.  
 
Massing and co-workers suggested in a previous study a new technique for bed-side 
preparation of bendamustin- liposomes by dual asymmetric centrifugation (DAC) [27]. An 
optimal protocol for EPC3/CH- liposomes was developed for entrapment of bendamustin. The 
entrapping efficiency was good (42% ± 4), and the particle size of the liposomes was small 
(62.5 nm ± 3.5). The bendamustin-liposomes were shown to be stable enough for application 
within one day. However, a rapid efflux of drug out of the liposomes was observed under 




The purpose of this project was to develop an improved liposomal formulation for 
bendamustin, using the DAC- technology. The goal was to find an optimal pH for the 
liposome formulation regarding stability and efflux of the drug, and thus prolong its half life 











Table 1: Lipids 
Name of lipid Article number Producer 
EPC3/CH 
998 ( molar ratio: 55/65) 




Table 2: Chemicals 
Chemicals 
 
Article number  Producer 
Acetonitril 1.14291.2500 Merck, Darmstadt, Germany 
AG 50W-X8 Resin 142-1441 BioRad Laboratories Inc. 
Munchen, Germany 












1.05099.1000 Merck, Darmstadt, Germany 
di-sodium 
hydrogenphosphate 
1.06580.0500 Merck, Darmstadt, Germany 
Dulbecco`s Modified Eagle`s 
Medium,modified 
formulation  
30-1002 ATCC®, USA 
Ethanol 96 % 5054.5 Merck, Darmstadt, Germany 
Hydrochloric acid 37 % 1.00317.1000 Merck, Darmstadt, Germany 




4873.1000 Merck, Darmstadt, Germany 
Lyso-
phophosphatidylcholine 
palmitoyl (purity 99%) 
L 5254 Sigma, Steinheim, Germany 
Methanol (LiChrosolv) 1.06018.2500 E.Merck,Darmstadt, 
Germany 
n-Hexane; C6H14 (p.a) 1.00573.2500 E.Merck,Darmstadt, 
Germany 




2- Propanol (p.a) 1.02790.1000 E.Merck,Darmstadt, 
Germany 
Ribomustin®   Ribosepharm 
Sodium chloride 1.06404.0500 Merck, Darmstadt, Germany 









Accusizer  PSS SWS 788 PSS Nicomp, California 
USA 
Analytic balance Mettler AT26119 Delta 
Range N85171 
Mettler Toledo, Giessen 
Germany 
Autosampler Waters 717 Autosampler 
(717003252) 
Waters, Eschborn, Germany 
 
Centrifuge, model J2-HC JGY93J11 Beckman coulter Gmbh 
Chromatogram Immersion 
device ΙΙΙ 
 Camag, Berlin, Germany 
DC-Automatic TLC Sampler 000214 Camag, Berlin, Germany 
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Eppendorf tubes (2 ml) 0020120.094 Eppendorf, Germany 
Glass beads - 1mm BBI-8541809 B. Braun Biotech Int. GmbH, 
Melsungen, Germany 
Glass chamber  Camag, Berlin, Germany 
Heating/drying oven 901001894 Binder, Tuttlingen, Germany 
Heater plate 93913 Desaga,Heidelberg, Germany
HPLC- system 








Waters 486 Tunable 
Absorbance Detector  
MX4MM8469M 
Waters, Eschborn, Germany 
 







Waters, Eschborn, Germany 
 
Pump control module 
 






Pre- column Lichrospher 60, RP select B 
4*4 mm (5 µm) 
 
Waters, Eschborn, Germany 
 
Column LiChrospher 60, RP- Select 
B 
VWR, Brucksal, Germany 
 
Column oven  
 
CHM-012670 Waters, Eschborn, Germany 
Temperature controller 
 




Waters, Eschborn, Germany 
Software 
 
Empower Pro 2, version 
6.00.00.00 




HPTLC-plates, Silicagel 60 1.05626 Merck, Germany 
Injection vial 10 ml, glass vial  
Injection vial 38 ml brown glass  
ISO 8362-4-JOH 
 
ZSCHEILE & Kinger GmbH 
Laboratory balance Mettler PM 4000  
(N88736) 
Mettler Toledo, Giessen 
Mini column separation LiChrolut incl. PTFE frits 
and glass columns 
Merck, Darmstadt, Germany 
Mixer, Vibrax VXR 00,059656 Electronic, Germany 
Photon correlation 
spectroscopy- PCS 
Submicron Particle sizer 
Model 370 (CW370) 
Nicomp Particle Sizing 
systems, California, USA 
pH meter Microprocessor PMX 3000 WTW GmbH  
Weilheim, Germany 
SpeedMixer  DAC 150 FVZ (DAZ) Hauschild, Hamm 
Stirrer Ikawag Ret-GS IKA Werke GmbH & co. KG 
Staufen, Germany 
Sterile Filter  Disposable filter holders 
0,45µm 
Sterile, pyrogenfree 
Schleicher &schnell GmbH 
Dassel, Germany 
TLC scanner ΙΙ, UV-
detection system 
991225 Camag, Berlin, Germany 
Vials/reaction tubes 16×100 
mm (with teflonlined screw 
stoppers) 
358646 Wheaton Millville, USA 








5.3 Media and solutions 
 
All the following solutions are given in examples of 1 L volume: 
 
0. 9 % Sodium Chloride solution 
- Used as hydration medium for preparation of VPGs, dilution medium for PCS 
measurements, and in efflux experiments. 
 
1. Sodium Chloride  9.0 g 
2. Distilled water      ad 1000. 0 g 
 
1.8 % Sodium Chloride solution 
- Used for preparing bendamustin-solution. 
 
1. Sodium Chloride  18.0 g 
2. Distilled water      ad 1000. 0 g 
 
Concentrated Sodium Chloride solution 
- Used for preparing ion-exchange columns 
 
1. Sodium Chloride  360.0 g 
2. Distilled water       ad  1000.0 g 
 
The Sodium Chloride was dissolved in distilled water by heating and stirring. The solution 
was filtrated through a 0.45 µm sterile filter into a flask for storage. 
 
Ethanol/Methanol (90/10 v/v) 
- Used for dissolving liposomes. 
 
1. 96% Ethanol    711.0 g 





Mobile phase HPLC method cholesterol 
Acetonitrile/methanol/acidic water (67/30/3 v/v/v): 
 
1. Acetonitrile       527 g 
2. Methanol       237 g  
3. Distilled water containing 3 drops of phosphoric acid 3 g 
      
Mobile phase HPLC method Bendamustin 
1) 
- Di-kaliumhydrogenphosphate- Trihydrate:    2. 3 g 
- Distilled water       ad   1000. 0 g 
- Phosphoric acid   adjust to pH     2.3 
 
Di-kaliumhydrogenphosphate-trihydrate (pH 2.3) / methanol (58/42 v/v): 
580.0 g of 1) ad 331.8 g Methanol  
 
PBS 150 mM (containing 10mM phosphate) pH 7.4 
- Used as aqueous medium for re-dispersion of liposomes. 
 
1. Sodium chloride    8.00 g 
2. Kalium chloride    0.20 g 
3. Di-sodium hydrogenphosphate  1.44 g 
4. Kalium di-hydrogenphosphate   0.24 g 
 
Ad 1 L distilled water 










PBS 150 mM (containing 30 mM phosphate) pH 2.0 
- Used as a hydration medium for preparation of VPGs for active loading. 
 
1. Kalium-dihydrogenphosphate  4.026 g 
2. Sodium Chloride    6.856 g 
3. Kalium Chloride    0.200 g 
 
- Ad 1.0 L distilled water. 
- Adjust pH to 2.0 with Hydrochloric acid. 
 
The same recipe was used for re-dispersion medium for the active loading experiment, except 
that the pH was adjusted to 4.5 with Hydrochloric acid. 
 
PBS 300 mM (containing 20 mM phosphate)  pH 2.0 
- Used for preparation of bendamustin-solution. 
 
1. Kalium-dihydrogenphosphate  2.68 g 
2. Kalium chloride    0.40 g 
3. Sodium chloride    16.00 g  
 
Ad 1.0 L distilled water 
Adjust pH to 2.0 with Hydrochloric acid 
 
Dulbecco`s Modified Eagle`s medium (DMEM), Modified Formulation 
 
Addition: 
- 10 % Fetalt bovint serum 
- 1% Penicillin  
- 1 % Glutamine  




5.4 Preparative methods 
 
5.4.1 Preparation of VPGs by dual asymmetric centrifugation 
 
Theory 
Dual-asymmetric centrifugation (DAC), also called speed-mixing, is a technique which is 
widely used by dentists to mix fillings out of two components. Recently the DAC has been 
presented as a homogenisation method for liposome preparation.  
 
DAC differs from normal centrifugation in that it contains two centrifugal units; one main 
rotator which is connected to a rotary arm containing the sample vial. While the main rotary 
basket is constantly pushing the sample material outwards due to centripetal forces, the 
additional rotation of the sample- containing- vial around its own vertical axis moves the 
sample material towards the centre of the centrifuge due to adhesion forces between the 
sample and the vial. The combination of the two contra movements result in shear forces, and 
hence in homogenisation.  
 
Optimal homogenisation is seen for viscous materials. This is simply due to the fact that 
inward movement of sample is dependent on the transfer of the adhesion forces into the 
sample, and this transfer is best for viscous materials. An optimal liposome production using 
DAC- homogenisation is obtained by using a viscous blend of phospholipids and buffer. The 
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Figure 13: Schematic drawing of the principals behind the mechanical forces involved in dual 
asymmetric centrifugation. 
 
Producing liposomes by DAC offers various advantages: 
 
- Sterile production and handling with toxic compounds is easy because preparation can be 
handled within a closed vial. The apparatus itself does not have to be cleaned before use.  
 
- VPGs are produced, which result in high entrapping efficiencies, especially for water soluble 
compounds. 
 
- Preparation of small batch sizes as well as bigger ones is possible. 
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- Preparation of liposomes is relatively fast. 
 
- Small debit to thermo- labile and unstable compounds. 
 




























Picture 1: Speed-Mixer 
 
 




In a previous experiment by Cicko, a protocol for production of EPC3/CH liposomes was 
developed [27]. For this investigation of variables which were thought to influence the 
particle size of liposomes prepared by DAC was carried out; different batch sizes, ratio of 
lipids and water, rotation-speed and time of speed-mixing, as well as size and amount of glass 
beads. The optimum of these parameters listed in table 4, is used in my further experiments. 
 
Table 4: Overview of different variables investigated in order to determine their influence on 
liposome size during speed-mixing.  
Parameters investigated Variables Optimum* 
Lipid amount 10, 25, 35, 40, 45, 50 % 35- 40 % 
Duration of agitation /time 
of speed-mixing 
1, 5, 10, 20, 30, 40, 50 min 30 min  
(no difference in longer time 
of speed-mixing) 
Speed of agitation in rpm 1000, 2000, 2500, 3000, 
3540 rpm 
3540 rpm 
Batch size 0.25, 0.5, 1.0, 2.0, 3.7 g  0.25- 3.7 g 
Amount and size of 
dispersion aids 
0.25- 0.3, 0.4-0.6, 1.0, 3.0 
mm  
1 mm in diameter, 
100 % amount of the batch 
size 




Preparation of VPG: 
The lipid mixture hydrogenated egg phosphatidyl choline and cholesterol (Epc3/CH) was 
blended with 0.9 % sodium chloride solution in the ratio of 40:60 m/m. Glass beads, in the 
size of 1 mm in diameter, were added in equal amounts with respect to the total weight of the 
batch size prepared. The VPGs were prepared by speed-mixing with maximum rotation speed; 






Re-dispersion of VPG: 
The VPGs were re-dispersed into liposome dispersions by adding aqueous medium in the 
ratio of 1:3. The solution was added 4 times, and speed- mixed for 30 seconds at 3540 rpm in 
between each added amount.  
 
i.e: For a batch size of 500 mg, 250 µl aqueous medium was added 4 times. In between each 
added amount, the VPG was speed mixed for 30 seconds at 3540 rpm. 
 
5.4.2 Preparation of bendamustin-containing VPGs 
 
5.4.2.1 Bendamustin-VPG formulation 1 
Preparation of bendamustin- solution:  
20 mg Ribomustin® powder, containing 45 % (m/m) bendamustin, was dissolved in 0.5 ml 
distilled water, and further diluted with 0.5 ml 1.8 % (v/v) sodium chloride solution.  
 
A 500 mg loaded VPG batch was prepared by adding 200 mg EPC3/CH, 300 mg of the 
bendamustin- solution and 500 mg glass beads (1 mm in diameter) to an ISO 8362-4-J0H 38 
ml injection vial. The blend was speed- mixed for 30 min at 3540 rpm.  
 
5.4.2.2 Bendamustin-VPG formulation 2 
The new bendamustin-VPG was prepared after the same recipe as for bendamusin-VPG 
formulation 1 described above, except that for preparation of the bendamustin solution 300 
mM PBS (containing 20 mM phosphate) pH 2.0 was used instead of 1.8 % sodium chloride 
solution. 
5.4.3 Active loading of bendamustin 
 
Theory 
Active loading is a process where drugs containing ionisable groups or display both lipid and 
water solubility can be introduced into liposomes after formation of the liposomes [28]. Such 
drugs are often difficult to retain inside the liposomes by normal means, since their 
lipophilicity leads to a passage through the membrane, readily, and thus equilibrating between 
the liposome interior and exterior. In an active loading, the conditions in the vesicle interior 
and in the outer aqueous phase are arranged in a way that the drug is capable of diffusing in 
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from the exterior, and once it reaches the interior it becomes ionized. This is often arranged 
by a pH difference between the inside and the outside of the membrane. After the solute 
enters the liposome by diffusion through the membrane in its uncharged form, it is converted 
to its ionized form. Consequently, the drug is unable to escape from the liposome, because its 
lipophilicity is highly reduced [28]. 
 
Experiment: 
An attempt of an active loading of bendamustin was carried out after the following procedure; 
 
Preparation of VPG: 
A 500 mg VPG batch was prepared by adding 200 mg EPC3/CH, 300 mg 150 mM PBS 
(containing 30 mM phosphate) pH 2.0 and 500 mg 1 mm glass beads to an ISO 8362-4-30H 
38 ml injection vial. The blend was speed- mixed for 30 min at 3540 rpm. 
 
The VPG was re-dispersed with 150 mM PBS (containing 30 mM phosphate) pH 4.5 in the 
ratio of 1:3, by adding 250 µl of the solution four times and speed-mixing at 3540 rpm for 30 
seconds in between each added amount. 
 
Preparation of bendamustin-solution; 
20 mg Ribomustin® was dissolved in 0.5 ml distilled water and further diluted with 0.5 ml 
0.9 % sodium chloride solution.  
 
Addition of bendamustin solution to the liposome dispersion:  
300 µl of the bendamustin- solution was added drop wise under continuously stirring of the 
re-dispersed VPG. The liposome-dispersion was kept on gentle stirring for 30 minutes at 
room temperature; 23 ºC.   
 
After 30 minutes 100 µl of the liposome dispersion was added to an ion exchange column (3 
parallels), according to section 6.2, and dissolved with ethanol/methanol (90/10 v/v) in the 
ratio of 1:100. As a reference 100 µl of the loaded liposome dispersion from the same VPG, 




Triplicates of the eluates and references were then ready to be injected and measured on to the 
HPLC system. Entrapped amount bendamustin within liposomes could be calculated 
according to equation 2 under section 5.5.2. 3 VPGs were prepared as parallels. 
 
5.5 Analytical methods 
 
5.5.1 Characterization of particle size by PCS 
 
Theory: 
Photon Correlation Spectroscopy (PCS) is an analytical tool to determine the size and size 
distribution of sub-micron particles suspended in a medium. The method is based on dynamic 
light scattering, and takes advantage of the time dependence of intensity fluctuation in 
scattered laser light due to Brownian motion of particles. The diffusion rate of particles varies 
according to their molecular weight and size. Small particles will diffuse more rapidly than 
bigger particles and will consequently give a more rapid fluctuation of scattered light 
intensity. Only a few changes in the position of a particle will give rise to significant changes 
in the phase to the scatter light waves [29], [30]. 
 
A laser light beam is sent through a cuvette containing the sample of interest. A detector, 
placed usually at 90º angle to the incident beam, is detecting the scattered laser light from the 
sample. The temperature must be held stable in order to ensure that viscosity is not changing 
and hence the diffusion rate of the particles. Based on a mathematical function called 
correlation, the diffusion coefficient is determined, and the particle radius can be calculated 
using the Stokes- Einstein equation. Depending on the power of the laser, it is possible to 
measure particles in the range of about 3 nm up to about 3 µm [29], [30]. 
 
Fitting and interpretation of the results 
Depending on the size-distribution of the sample, the software evaluates the data using two 
different models; The Gaussian model and the Nicomp model. The Gaussian model states 
how well a fit is approaching a normal distribution. The goodness of the fit is given by the Chi 
squared. If the data perfectly follow a normal distribution the Chi squared is close to 0. If the 
Chi squared is > 3, the data do not show a good fit to the normal distribution, and 
interpretation of the data should be done by the more advanced Nicomp model [31], [32]. 
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The Nicomp model is suitable for polydisperse samples having two or more distinct 
populations of different particle sizes. The model then calculates a mean of several 
populations of particles in the sample. As an indication of how stable the results of the 
analysis are, the PCS software gives a value for Fit error. For reliable results using the 
Nicomp model, the fit error should be below 1.5 and preferably near 0 [31], [32]. 
 
Polydispersity index (P.I.) is stating how broad the distribution is around the mean particle 
size. Highly polydisperse samples, containing particles with different sizes, will show a high 
P.I. value close to 1. For liposome formulations the P.I. is often of importance because 
different applications demand a particle size in a certain size-range. A low P.I. value, close to 
0, is therefore most often desirable. However, based on empirical data, liposome dispersions 
in general do often show a certain polydispersity. 
 
For reliable results one has to make sure that there is no particular presence of contaminants 
in the sample. This can be seen in the Gaussian model as the “baseline adjust” and in the 
Nicomp model as the “residual”. These parameters should be close to zero [32]. 
 
Channel width or channel sampling time is a conception used to describe the width of the 
autocorrelator channel intervals the sequence of photon pulses from the detector is divided 
into [31]. The sample time should ideally correspond roughly to the frequency of signal 
fluctations. The channel width can be adjusted as required, depending on the particle size and 
distribution in the sample. Choosing a too small channel width, the bigger particles in the 
sample, with the slowest fluctations, will be excluded from the measurement. Subsequently, a 
too broad channel width will often result in only a few channels responding to scattered light. 
The choice of channel width is important in order to ensure that sufficient information is 
acquired to enable a full plot of the correlation curve. A too small or too big channel width 
might result in an auto correlation function that decreases too fast or too slow, respectively. 
Consequently, the results can be incorrect with respect to particle size and size distribution 
[32]. 
 
In order to ensure high degree of statistical accuracy, the amount of photon pulses data 
collected by the auto correlator, used to calculate the auto correlation function, should ideally 
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exceed one million (1000 K) [33]. The amount of data collected is dependent on the time of 
measuring as well as the selected channel width [29]. 
 
Experiment: 
Re-dispersed VPGs were further diluted with 0.9 % sodium chloride solution by manual 
shaking until reaching a suitable intensity level of 250-350 KHz as stated in the Nicomp user 
manual [32]. 
 
Before measurements were performed the instrument parameters were set according to the 
values listed in table 5. To ensure statistical accuracy, two cycles of 10 min were run for each 
sample in order to collect a big amount of collected data.  
 
Table 5: PCS parameters 
Parameters Value 
Temperature 23 C° 
Viscosity 0.933 cp 
Liquid index of refraction 1.333 
Intensity set point 300 ± 50 
Channel width Auto set, 20, 10 and 5 µs 
 
5.5.2 Determination of ratio of entrapped/unentrapped bendamustin  
 
Theory  
In order to determine encapsulation efficiency of bendamustin or incorporated bendamustin 
within liposomes over time, the external bendamustin in the outer aqueous phase of the 
liposome-dispersion has to be removed. One method suited for this is ion- exchange 
chromatography. 
 
Ion exchange chromatography relies on charge-charge interactions between the charges of 
dissolved spices and the charges immobilized on the resin used. For bendamustin, cation- 
exchange chromatography was used. Cation- exchange chromatography is based on the fact 
that positively charged ions bind to a negatively charged resin. External bendamustin in the 
outer aqueous phase will bind to the resin in the column, while incorporated bendamustin 
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within the liposomes will not. Hence, only the liposomal bendamustin will pass through the 
column and can be collected in a flask.  
 
Experiment 
The following ion-exchange method was the first method used for separating liposomal 
bendamustin from external bendamustin. (The method was taken from personal 
communication within the working group of Massing at the Tumour Biology Centre, 
Freiburg, Germany.) 
 
Preparation of the Lichrolut cation exchange column: 
 PTFE-frits were placed within the glass column. 
 1g of AG-50W-X8 Resin was added to the glass column. 
 The column was filled with distilled water and left still in 5 minutes in order to get 
sedimentation of the resin. 
 Excess water was removed by vacuum until only the top of the resin was covered with 
water.  
 The glass column was loaded three times with 1.0 ml filtrated concentrated sodium 
chloride solution, and thereafter flushed three times with 1.0 ml distilled water. Finally 
the glass column was dried by full vacuum for 5 minutes. 
 
Separation of liposomal bendamustin from external bendamustin by ion-exchange 
chromatography 
 50 µl of the liposome dispersion was added dropwise to the column followed by 
vacuum suction.  
 The column was flushed five times with 125 µl distilled water under continuous 
vacuum suction.  
 The eluate, containing only liposomal bendamustin, was collected in a flask.  
 
In order to correct for potential loss of liposomes on the columns (liposomes not coming 
through the resin), cholesterol in the eluate was measured and compared to a reference sample 
from the same sample set, not applied to the column. The amount cholesterol in the Epc3/CH 
powder is 27.3 % per weight. After re-dispersion of the VPG and further dilution of 1:100, the 
theoretically concentration of cholesterol in the sample is 364 µg/mg.  If all the liposomes 
have gone through the column and been collected in the flask, the cholesterol concentration in 
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the eluate should be the same as for the reference, which in turn should correspond to about 
the theoretical amount of cholesterol. As a correction for possible loss of liposomes on the 
columns, cholesterol recovery was measured using equation 1. 
 
Equation 1:   
 
 Cholesterol recovery % = (Cholesterol in eluate/ Cholesterol in reference) ×100 
 
 
Approaches for optimization of ion exchange chromatography regarding cholesterol recovery. 
Cholesterol recovery in the liposome-eluates separated by the columns prepared as described 
above, should be quite equal, and not vary between the columns used. Moreover, previous 
experience from similar ion-exchange chromatography methods has shown stable cholesterol 
recoveries above 80 %. Different approaches were carried out in order to optimize the cation-
exchange method for bendamustin described above, regarding cholesterol. These approaches 
are described in section 6.2. 
 




HPLC is a form of column chromatography used to separate components of a mixture by the 
variety of chemical interactions between the substance being analyzed, analyte, and the 
chromatography column, stationary phase. Reverse phase chromatography consists of a non- 
polar stationary phase and a moderately polar mobile phase, and is used in these experiments 
to separate both bendamustin and cholesterol from other components in the sample such as 
ethanol/methanol and lipids. A small volume of the sample being analyzed is injected into the 
stream of the mobile phase which is pumped through the column at high pressure. When the 
sample is passing through the column, non polar molecules interact with the stationary phase 
and are retarded [34]. 
 
 In order to quantify the bendamustin or cholesterol concentration in the samples of interest, a 
series of known concentrations are injected onto the HPLC for detection. The chromatographs 
of these known concentrations will give a series of peaks that correlate to the concentration of 
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the compound injected. A calibration curve is generated by calculating the area under the 
peak. Using a calibration curve, unknown concentration of bendamustin or cholesterol in the 
sample can be executed [34]. 
 
Experiments 
The liposome eluate, separated from external bendamustin by the optimized ion exchange 
chromatography method described in section 6.2, was diluted with ethanol/methanol (90/10 
v/v) in the ratio of 1:100 in order to dissolve the liposomes.  
 
As a reference, an aliquot from the same liposome dispersion, containing the overall 
bendamustin content, was diluted in ethanol/methanol (90/10 v/v) in the ratio of 1:100.  The 
bendamustin concentration as well as the cholesterol concentration in both the eluate and in 
the reference could subsequently be determined by RP-HPLC. Throughout all the experiments 
triplicates for both the eluates as well as references were prepared. 
 
Quantification of bendamustin by RP-HPLC 
 
The parameters used for quantification of bendamustin by RP-HPLC are listed in table 6. 
 
Table 6: HPLC parameters used for quantification of bendamustin 
Column Lichrospher 60 RP-select B (5µm) 250 × 4 
mm 
Packing material column C-8 
Injection volume 10 µl 
Mobile phase PBS(di-Kaliumhydrogenphosphate- 
Trihydrate) pH 2.3 / Methanol 58/42 (v/v) 
Flow rate  1.0 ml/min 
Column temperature 30 °C 
UV detection wavelength 254 nm 
Retention time  Ca 10 min 
Calibration range 2- 64 µg/ml 
6 calibrators: 2, 4, 8, 16, 32, 64 µg/ml 
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A calibration series of bendamustin was developed by plotting the area under the curve 
(AUC) from the peaks versus the concentration of the samples.   
 
Preparation of a calibration series bendamustin: 
Stock solution: 
5 mg Ribomustin® was dissolved in 2.5 ml distilled water and further diluted with 2.5 ml 1.8 




1.760 ml of the stock solution was added to a 10 ml graduated flask. The flask was filled up 
with 0.9 % sodium chloride solution. The concentration of bendamustin in this dilution is 80 
µg/ml. 6 calibrators were prepared as listed in table 7. 
 
Table 7: Calibrators bendamustin 
Calibrator nr Concentration µg/ml Ad dilution 1  Fill up with 0.9 % 
Sodium-chloride 
solution to 
1 2 125 µl 5 ml 
2 4 250 µl 5 ml 
3 8 500 µl 5 ml 
4 16 1000 µl  5 ml 
5 32 2000 µl 5 ml 










As seen from figure 14, the calibration series reveals a good linear fit with a R2 value of 
0.999995.  
(The range of R2 values for all of the calibration lines for bendamustin prepared throughout 
the experiments were: 0.99665 – 0.999998.) 
          
          R2 = 0,999995 
 
Figure 14: Calibration line for bendamustin, showing AUC over amount bendamustin in 
µg/ml. 
 
An example of a typical chromatogram of a sample of bendamustin is shown in figure 15. The 




Figure 15: Example of a typical chromatogram of bendamustin.  
 
Quantification of Cholesterol by RP-HPLC 
 
Measurement of cholesterol was carried out as a correction factor for the ion-exchange 
chromatography. 
 













Table 8: HPLC parameters used for quantification of cholesterol 
Column Lichrospher 60 RP-select B (5µm) 250 × 4 
mm 
Packing material column C-8 
Injection volume 10 µl 
Mobile phase  Acetonitrile/methanol/acidic water (67/30/3 
v/v/v) 
Flow rate  1 ml/min 
Column temperature  40 ºC 
UV detection wavelength 215 nm 
Retention time Ca 6 min 
Calibration range 100-800 µg/ml 
5 calibrators: 100, 200, 300, 400, 800 µg/ml 
 
A calibration series of cholesterol was developed by plotting the area under the curve (AUC) 
from the peaks versus the concentration of the samples.   
 
Preparation of calibration series cholesterol: 
14 mg cholesterol was dissolved in 5 ml ethanol/methanol (90/10 v/v), resulting in a 
concentration of cholesterol of 2660 µg/ml. 
 
Stock solution: 
The 2660 µg/ml cholesterol solution was further diluted to yield in a stock solution containing 










Table 9: Calibration series cholesterol 
Calibrator nr Concentration µg/ml Ad stock solution µl Fill up with 
ethanol/methanol 
(90/10 v/v) in ml 
1 100 200 5  
2 200 400 5 
3 300 600 5 
4 400 800 5 
5 800 1600 5 
 
As seen from figure 16, the calibration series reveals a good linear fit with a R2 value of 
0,999691. The range of R2 values for all of the calibration series prepared for cholesterol used 
throughout the experiments were: 0.996708- 0.999694. 
 
          R2 = 0.999691  
 
 
Figure 16: Calibration line cholesterol. 
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An example of a typical chromatogram of cholesterol is shown in figure 17. The peak in this 
chromatogram corresponds to a cholesterol concentration of 363,048 µg/ml. 
 
 
Figure 17: Example of a typical chromatogram of cholesterol.  
 
Encapsulation efficiency or entrapped amount liposomal bendamustin was determined using 





EE % = 100 /  (reference bendamustin) x (eluate bendamustin) 








5.5.3 Degradation of bendamustin during speed-mixing. 
 
Degradation of bendamustin during speed-mixing of the loaded VPGs was investigated as 
follows; 
 
Bendamustin-VPG formulation 1 as well as bendamustin-VPG formulation 2 were prepared 
according to section 5.4.2.1 and 5.4.2.2 respectively, and re-dispersed with 0.9 % sodium 
chloride solution according to section 5.4.1. 
 
Immediately after re-dispersion of the VPGs, aliquots of the liposome dispersion were 
dissolved in ethanol/methanol (90/10 v/v) in the ratio of 1:100. The overall bendamustin-
content in the re-dispersed VPGs was measured on RP-HPLC and compared with the 
theoretical concentration bendamustin in the liposome dispersion diluted 1:100. 
 
Triplicates for each of 3 VPGs were prepared and measured as parallels. 
 
5.5.4 Stability of bendamustin-solution at pH 7.4  
 
Stability of bendamustin in pH 7.4 at 23 ºC and 37 ºC was measured after the described 
method; 
  
Preparation of Bendamustin/ PBS solution: 
5 mg Ribomustin® was dissolved in 20 ml 150 mM PBS buffer (containing 10 mM 
phosphate),  resulting in a concentration of 0.114 mg/ml bendamustin.  
 
The solution was further diluted with the same PBS buffer to yield in a bendamustin- 
concentration of 32 µg/ ml, which is a concentration within the calibration line. 
 
The solution was incubated at 23 ºC as well as at 37 ºC. After the following time points an 
aliquot was taken out and injected onto the HPLC system: 0, 5, 10, 15, 20, 30, 40 and 60 
minutes. Triplicates were prepared for each time point and remaining intact bendamustin was 
measured on HPLC according to section 5.5.2 
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5.5.5 Efflux experiments of liposomal bendamustin 
 
Release experiments of liposomal bendamustin were carried out. Loaded liposomes were 
incubated at 37 ºC and at various time points the samples were assayed with respect to loss of 
incorporated drug. All the efflux experiments were carried out after the following general 
description;  
  
A loaded VPG was prepared and re-dispersed into liposome dispersions in the ratio of 1:3 by 
adding 250 µl aqueous medium four times, and speed-mixing for 30 seconds at 3540 rpm in 
between each added amount.   
 
The liposome dispersion was incubated in eppendorf cups at 37 ºC. At different time-points 
aliquots of the liposome dispersion were applied to ion-exchange columns, according to 
section 6.2 for removal of external bendamustin. 
 
Both, the liposomal bendamustin and references containing the overall bendamustin content 
from the same sample set were determined at each time point. In order to crack the liposomes 
the samples were collected in graduated flasks and diluted with ethanol/methanol (90/10 v/v) 
in the ratio of 1:100. 
  
Triplicates from the liposome dispersion were prepared at each time point. (eluates from 3 
columns as well as 3 references) For practical reasons, maximum 5 time points were 
measured in one run. Several VPGs were therefore prepared, and amount of liposomal 
bendamustin was determined at different time points for the respective VPGs, until the efflux-
curve was executed. (The VPGs had shown to be reproducible regarding EE as well as 
particle size, and was therefore expected to show the same efflux kinetics.) 
 
The samples were injected into the RP-HPLC system for quantification of bendamustin as 
well as cholesterol before the lipsomal bendamustin per time point was calculated using 




5.5.6 Stability experiments  
 
Stability of the new bendamustin liposome-formulation was investigated in respect to 
degradation of bendamustin and lipids upon storage in room-temperature 23 °C, as well as 
stability in cell culture medium at 37 °C.  
 
5.5.6.1 Stability of liposomal bendamustin at room temperature 
A bendamusin-VPG formulation 2 was prepared according to section 5.4.2.2 and re-dispersed 
in the ratio of 1:3 with 150 mM PBS (containing 10 mM phosphate) pH 2.0, by adding 250 µl 
of the PBS solution four times and speed-mixing at 3540 rpm for 30 seconds in between each 
added amount. 
 
Aliquots of the re-dispersed VPG were incubated in eppendorf cups at 23 ºC (room 
temperature) for the following time points:  0, 1, 2, 16, 21 and 24 hours.  
 
At the respective time points the samples were dissolved with ethanol/methanol (90/10 v/v) in 
the ratio of 1:100, and injected onto the RP-HPLC system in order to measure intact 
bendamustin. Triplicates were prepared at each time point.  
 




The principle of Thin-layer chromatography of lipids is, as for all chromatographic methods, 
the fact that two different, immiscible phases can be used to separate compounds based on the 
compounds characteristics and their respective affinities for the phases.  
 
For phospholipids the stationary phase is most often silica gel which is moderately 
hygroscopic and consists of spherical granules coated with a layer of tightly bound water. The 
mobile phase is usually a mixture of organic solvents including chloroform. Under these 
conditions, phospholipids are separated principally according to differences in their head 
groups, which in the liquid organic phase will have unlike affinities for the hydrophilic solid 
phase. As the liquid phase runs through the solid phase, the dissimilar phospholipids will be 
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retained to different extent by the solid phase, and will consequently spread out at different 
distances behind the solvent font [35]. 
 
Most often lipids are visualized by means of specific bands which are sprayed on to the plate. 
Together with standards of known concentrations, the samples of interest can be detected by 




Stability of lipids in the bendamustin-liposomes compared to “empty” liposomes was 
investigated after the following method; 
 
Sample preparation and incubation: 
One bendamustin- VPG was prepared according to section 5.4.2.2. As a reference an “empty” 
VPG was prepared according to section 5.4.1 by using 150 mM PBS pH 2.0 as aqueous 
medium. Both the “empty” VPG and the loaded VPGs were re-dispersed in the ratio of 1:3 
with 150 mM PBS pH 2.0, by adding 250 µl of the PBS solution four times and speed-mixing 
at 3540 rpm for 30 seconds in between each added amount. 
 
The liposome dispersions were stored at 23 ºC /room temperature for the following time-
points; 0 min, 1 hour, 2 hours and 24 hours.  
 
At the respective time-points 90 µl of the gel-dispersions were diluted with 0.9 % sodium 
chloride solution to yield in a final concentration of 8 mM, and mixed for 2 minutes at 200 
rpm. The samples were immediately extracted in order to stop any further reaction.   
 
Duplicates for each of the two VPGs were prepared and measured in the same way.  
 
Extraction: 
The samples were transferred to 10 ml glass tubes. 2 ml chloroform/methanol (2:1 v/v) were 
added and mixed for 5 minutes at 1000 rpm/min. The tubes were centrifuged for 10 minutes at 
4 ºC, 4000 rpm, before the chloroform phase was pipetted to another glass vial and evaporated 
to dryness at 40 ºC under a weak steam of nitrogen. The remaining water phase was extracted 
the same way for two more times, and the chloroform phase was always collected in the same 
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tube and evaporated. The samples were then re-dissolved in Hexan/2-Propanol/H2O 40/50/8 
(Concentration factor 2 to 3.1).  
 
HPTLC:   
The HPTLC plates used were pre-run with mobile phase CHCl3/MeOH/H2O/NH3 
(65/25/4/0.4 per volume). Approximately 7 µl of each sample were sprayed as bands 
automatically with a TLC sampler ΙΙΙ. The distanced between the 14 mm bands were 2.6 mm. 
Application were executed with a spraying speed of 70 nL/s and a horizontal speed of 7 
mm/sec.  
 
The plates were developed in a glass tank with the mobile phase, run distance: 9.0 cm. After 
development, plates were dried for 10 minutes at 180 ºC on a heating plate.  
 
Visualizing of lipids occurred by dipping the plate 3 times for 2 seconds in a copper sulphate 
solution (14.7 % w/v) in phosphoric acid (10 % v/v). The plates were then dried in an oven at 
160 ºC for 6 minutes.  
 
The spots were read quantitatively using a TLC-Scanner ΙΙ at 530 nm with a wolfram lamp in 
reflexion mode at the following conditions: 
 
- Speed of measurement: 0.1 mm/s 
- Sensitivity: Ca. 125 
- Span Ca. 7 
- Monochromator 30 nm 












A calibration range from 1 to 5 % Lyso-PC according to the reference amount of 8 mM EPC3 
was prepared as follows; 
 
Lyso-PC stock solution: 
10 mg Lyso-PC was dissolved in 20 ml 0.9 % Sodium chloride solution. 
 
Lyso-PC dilution 1 
The stock solution was further diluted to yield in a concentration of 1000 µM.  
 
Table 10: Calibration solutions Lyso-PC 
Calibrators Addition of 
dilution 1 (µl) 
Filled up to (ml) 
with NaCl 
solution 




EPC3 (%) * 
1 800 10 40 0.5 
2 1600 10 80 1.0 
3 2400 10 160 2.0 
4 3200 10 320 4.0 
5 4000 10 400 5.0 
6 4800 10 480 6.0 
* Reference concentration EPC3 is 8000 µM 
 
For each analysis 1 ml calibrator was used. After extraction procedures the calibrators were 











5.5.6.3 Stability of bendamustin-liposomes in comparison to free bendamustin- solution upon 
incubation in cell culture medium. 
 
Stability of the new bendamustin-liposome formulation was tested and compared to the free 
drug in cell culture medium as follows; 
 
- Incubation of bendamustin-liposome formulation 2 in cell culture medium: 
Bendamustin-VPGs formulation 2 were prepared according to section 5.4.2.2, and re-
dispersed in cell culture medium in the ratio of 1:6, by adding 250 µl of the medium four 
times, and speed-mixing for 30 seconds at 3540 rpm in between each added amount. Then, 
1.5 ml of the same medium was added to the dispersion and speed-mixed for another 30 
seconds in order to get a proper liposome suspension. 
 
Aliquots of the sample were added to eppendorf cups and incubated at 37 ºC for the following 
time points: 0, 5, 15, 20, 30, 60, 120 and 240 minutes. 
 
At the respective time points the aliquots were dissolved with ethanol/methanol 90/10 (v/v) in 
the ratio of 1: 100. The diluted samples were then centrifuged for 10 minutes at 4 ºC. This 
was done in order to separate proteins in the medium from the samples, which are prone to 
clog in the HPLC- system during measurement. Triplicates were prepared for the respective 
time- points for each of in total 3 VPGs. Intact bendamustin at each time point was quantified 
on HPLC according to section 5.5.2. 
 
- Incubation of free bendamustin- solution in cell culture medium:  
20 mg Ribomustin® powder was dissolved in 0.5 ml distilled water, and further diluted with 
0.5 ml 300 mM PBS pH 2.0. (This bendamustin-solution is the same as used for preparation 
of the bendamustin-VPGs.) 
 
300 µl of the bendamustin-solution was added to 2.7 ml cell culture medium pH 7.6, in order 
to get the same dilution ratio as for the liposome samples.  
 
Aliquots of the sample were added to eppendorf cups and incubated at 37 ºC for the following 
time points: 0, 5, 15, 20, 30, 60 and 120 minutes.   
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At each time point the solutions were diluted in ethanol/methanol 90/10 (v/v) and centrifuged 
for removal of proteins in the same way as for the liposome dispersions described above. 
Triplicates at each time point were prepared for in total 3 bendamustin-solutions incubated in 
medium. Intact bendamustin were assayed on HPLC according to section 5.5.2. 
 
6 RESULTS AND DISCUSSIONS 
 
6.1 Size and size- distribution of liposomes prepared by DAC 
 
Size and size-distribution of “empty” VPG batches prepared in two vials with different radius 
and size. 
 
The extent of mechanical energy applied during preparation of liposomes, is known to have 
impact on the size and size-distribution of liposomes [24]. One important factor which is 
affecting the centrifugal force on a basket which is rotating is its radius. The bigger the radius 
of the basket, the stronger is the force exerted on its contents. It is therefore reason to assume 
that the radius and size of sample-vials used during speed- mixing could influence the size 
and size- distribution of the liposomes formed.  
 
The following VPG batches were prepared according to section 5.4.1; 100, 200 and 500 mg. 
Each batch- size was prepared in both a 38 ml glass vial (diameter 5 cm) and in a 10 ml glass 
vial (diameter 2 cm). 3 parallels of each batch- size were prepared in both of the two vials in 
order to investigate reproducibility of the size and size-distribution of VPGs prepared by 
DAC. The VPGs were re-dispersed in the ratio of 1:3 with 0.9 % sodium chloride solution, 
before the samples were further diluted and measured on PCS according to section 5.5.1. 
  
For all the PCS measurements, only channel width 5 µs and 10 µs were fittable by the 
Gaussian model. Autoset and Channel width 20 µs showed a Chi squared > 3. This indicated 
that the samples revealed a polydisperse particle- size distribution; i.e presence of liposomes 
of different sizes. The data was neither, for most of the measurements, fittable by the Nicomp 
model (Fit error > 1.5).  
 
 53
Presence of bigger particles in a sample measured has the tendency to overshadow smaller 
particles, and the mean diameter calculated by the software is bigger than the actually ones. In 
order to calculate the data from a rather polydisperse sample by a Gaussian distribution, the 
software suggest to reduce the channel width, taking only a proportion of the total signal into 
calculation of the diffusion coefficient. The drawback with this is that the correlation function 
plot created is not as long as desired, and might give values derived from the diffusion 
coefficient that is not so accurate [35]. However, this inaccuracy is most probably systematic 
making the results of the different batches prepared in their respective vials still comparable. 
Moreover, the results should give a rough estimate of the size and size-distribution of the 
liposomes prepared. 
 
The data collected were for the Autoset channel width above 1000 K for all measurements. 
For Channel width 10 µs and 5 µs the amount of data were lower; range 186-592 K.  
 
As presented in figure 18, there was no difference in the mean particle- size distribution for 
the different VPG batches prepared in the two vials. The results show that one can achieve a 
liposome size of about 60 nm by speed-mixing 100 mg, 200mg and 500mg VPG batches for 
30 min (3540 rpm), using either the 38 ml -or the 10 ml glass container.  
 

































































Figure 18: Mean particle size of different VPG batches prepared by speed-mixing in two vials 
with different radius and size. 
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One explanation why there is not seen any difference in particle size between the VPGs 
prepared in the two vials might be that the mean diameter calculated is not a sensitive 
indicator able to indicate potensial differences, which in turn makes the applied analytical 
method  suboptimal. Moreover, it might be that the difference in radius between the two vials 
is not big enough to make a significant difference on the results.  
 
As seen from figure 19 the polydisperity indexes for the different VPGs prepared show quite 































































Figure 19: Polydispersity index of different VPGs batches prepared by speed-mixing in two 
vials with different size.  
 
The polydispersity indexes indicate that the samples contain a rather broad particle- size 
distribution. As seen from figure 19 there is a tendency of smaller P.I. values for the VPG 
batches prepared in the biggest vial. This indicates that there might be a difference in size-
distribution between the VPGs prepared in the different vials. In the bigger vial the sample 
material might be more evenly forced towards the walls of the vial, resulting in a more 
homogenous particle size distribution. In addition, the standard deviations between the VPGs 
prepared in the biggest vial seem to be a bit smaller than for the VPGs prepared in the 
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smallest vial, thus indicating more reproducible results regarding size-distribution of the 
liposomes. Based on these findings, the 38 ml vial should be chosen in preference to the 10 ml 
vial for the respective batches investigated.   
 
Size and size-distribution of bendamustin-liposomes 
Particle size of the bendamustin-liposomes was investigated in order to see if the presence of 
bendamustin within the liposomes, as well as the low pH of 2.0 in the new bendamustin-
liposome formulation 2, could alter the size of the vesicles in comparison to the “empty” 
liposomes. Bendamustin-liposome formulation 1 and 2 were prepared according to section 
5.4.2.1 and 5.4.2.2 and measured on PCS according to section 5.5.1.  
 
The results presented in table 11 show a particle-size of about 60 nm for both of the 
bendamustin-liposome formulations as well as for the “empty” liposomes. 
 
Table 11: Particle size and size-distribution of “empty” VPGs in comparison to bendamustin-
VPG formulation 1 and bendamustin-VPG formulation 2. (Channel width 10 µs) 
VPG formulation Mean particle size (nm) 
and SD 
P.I. and SD 
 Bendamustin-VPG 
formulation 1 
62.8 ± 2.0 0.53 ± 0.01 
Bendamustin-VPG 
formulation 2 
60.5 ± 1.3 0.50 ± 0.01 
“Empty” VPGs 51.6 ± 3.0 0.70 ± 0.06 
 
The liposome size and distribution was found not to be affected by presence of bendamustin 
within the liposomes. This results corresponds to a previous measurement carried out by 
Cicko[27]. 
 
There is a chance, however, that the particle size of the new bendamustin-liposome 
formulation 2 might change after long term storage due to the pH of 2.0 in the VPG. The low 
pH might alter the lipid membrane and accelerate physical instability processes such as fusion 
of liposomes, when diluted [22]. Consequently, particle size might increase over time. 
However, considering the fact that the formulation is intended as a bed-side preparation, this 
should not be a problem regarding stability of the formulation. 
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6.2 Optimization of ion exchange chromatography method for 
bendamustin 
 
The first cation- exchange chromatography method used, as described under section 5.5.2, 
showed a great variance in cholesterol recovery between the liposome-eluates separated from 
the columns prepared; SD 16.7 %. In addition the recoveries were relatively low; mean 
cholesterol recovery calculated from the eluates was 49.8 % (See appendix for details). The 
great variance in cholesterol recovery in the eluates separated from the columns indicated that 
the cation- exchange method was suboptimal. Three different approaches of improving the 
method by obtaining a higher cholesterol recovery as well as a lower variance in cholesterol 
between the eluates were carried out as described below. 
 
Approach 1  
A VPG was prepared and re-dispersed in 0.9 % sodium chloride solution according to section 
5.4.1. The same ion-exchange method described under section 5.5.2 was carried out with the 
exception that all the amounts for both column- preparation as well as for sample application 
and flushing of sample was doubled;  resin, sodium chloride solution and water used for 
column preparation, liposome sample as well as water used for flushing of the liposomes.  
 
The eluates and the references (not applied to the columns), were diluted with 
ethanol/methanol (90/10 v/v) in the ratio of 1:100 in order to dissolve the liposomes. 
Cholesterol in the samples was measured on RP-HPLC and cholesterol recovery was 
calculated using equation 1 according to section 5.5.2 
 
The results showed considerable less variance in cholesterol recoveries between the eluates 
from the columns. In addition the recovery was considerable higher; Mean cholesterol 
recovery calculated from equation 1 under section 5.5.2 was; 74 % ± 8.5 (See appendix for 
details). 
 
A SD of 8.5 % is an acceptable variance in cholesterol recovery between the eluates. The 
ratios between the critical parameters as amount of sample, resin, and water for flushing were 
the same in this approach as in the first method described in section 5.5.2, and in this respect 
the cholesterol recovery should theoretically be the same for the two methods. There could be 
a problem, however, that the amount of sample applied to the columns in the first method, 
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was too small to handle, and therefore better results were seen when double amount of sample 
was used.  
 
Approach 2   
Although lower variance in cholesterol recovery between the eluates was obtained in 
approach 1, the cholesterol recovery was still a bit low; 74 %. One theory explaining the 
rather low cholesterol recovery could be suboptimal dissolution of liposomes in the eluates in 
dilution 1:100 of ethanol/methanol (90/10 v/v), even though the solutions seemed clear. The 
theoretical concentration of cholesterol in this dilution is 364 µg/ml. The references from the 
same sample set, not applied to columns, showed a cholesterol concentration of about 100 % 
of the theoretically cholesterol value in the respective liposome dilution (See appendix for 
details). This stated that the liposomes were totally dissolved in the reference samples. In the 
eluates, however, the amount of water which was added in the flushing step could result in a 
dissolution problem of the liposomes.  
 
In order to investigate if low cholesterol recoveries were due to suboptimal dissolution of the 
liposome-eluates, the following approach was carried out;  
 
A VPG was prepared and re-dispersed with 0.9 % sodium chloride solution according to 
section 5.4.1. 100 µl of the liposome sample was added to each of two 10 ml graduated flasks. 
The liposomes in the one flask was diluted with 1.25 ml distilled water, which was the same 
amount of water used during the flushing step of ion-exchange chromatography, and then 
further diluted with ethanol/methanol (90/10 v/v). The liposomes in the other flask was 
diluted only with ethanol/methanol (90/10 v/v). Both of the liposome samples yielded in a 
dilution of 1:100. Triplicates were prepared for both the sample containing water, as well as 
for the reference, before cholesterol was measured on RP-HPLC according to section 5.5.2. 
 
The results indicated, however, no difference in the cholesterol concentration between the 
samples containing water and the references (diluted only in ethanol/methanol); Cholesterol 
concentration of 399 µg/ml ± 4.2 for the samples containing water, and 402 µg/ml ± 7,2  for 
the references (See appendix for details). These cholesterol values were within the range of 
the theoretical cholesterol concentration of 364 µg/ml, in the respective dilution. 
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Based on these findings the liposomes in the eluates, containing 1.25 ml water + 
ethanol/methanol (90/10 v/v) were properly dissolved. Hence, the reason for the low 
cholesterol recovery was not due to suboptimal dissolution of the liposome- eluates.  
 
Approach 3 
Another explanation for the low cholesterol recoveries could be that the amount of water used 
for flushing was too small, leading to suboptimal flushing of liposomes through the resin of 
the columns. More water for flushing would lead to a dissolution problem of the liposomes in 
dilution 1:100. Furthermore, a higher dilution with ethanol/methanol would result in a 
bendamustin concentration under the UV detection range, and was therefore not possible. 
However, by reducing the resin amount, and keeping the water amount stable, more water per 
resin would be obtained for flushing.  
 
First, columns were prepared according to section 5.5.2. Then resin capacity was checked in 
order to see if 1 g of resin was sufficient for keeping all the external bendamustin attached to 
the resin. For this 4 mg Ribomustin® was dissolved in 0.5 ml distilled water and further 
diluted with 0.5 ml 1.8 % sodium chloride solution, yielding in the same bendamustin-
concentration as for the re-dispersed VPG; 1.82 mg/ml bendamustin. 
 
Furthermore, VPGs were prepared and re-dispersed with 0.9 % sodium chloride solution 
according to section 5.4.1. The amount of liposome-sample applied to the columns as well as 
the water amount used for flushing was doubled; 100 µl of the liposome dispersion was 
applied to each of the columns. The columns were then flushed five times with 250 µl 
distilled water under continuous vacuum suction.  
 
All the eluates and references were dissolved in ethanol/methanol (90/10 v/v) in the ratio of 
1:100. Potential bendamustin in the eluates from the resin-capacity test was quantified on RP-
HPLC. Cholesterol was measured for the liposome-eluates on RP-HPLC before cholesterol 
recovery was calculated using equation 1 according to section 5.5.2. 
 
The results from the resin-capacity test showed no detected bendamustin in the eluates 
measured on HPLC, which stated that all of the bendamustin was left in the resin, and 
concenquencly the resin-capacity was satisfying. 
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The variance in cholesterol recoveries from the liposome-eluates showed a low standard 
deviation, in addition to increased recovery; 86 % ± 3. Hence, the reason for the low 
cholesterol recoveries was due to suboptimal water per resin used in the flushing step of the 
liposomes. The improved ion-exchange method for bendamustin, described below, was used 
further on in this study; 
 
 Improved Ion- exchange chromatography method for bendamustin: 
 
Preparation of the Lichrolut cation exchange column: 
 PTFE- frits were placed within the glass column 
 1 g of AG 50W-X8 Resin was added to the glass column 
 The column was filled with distilled water and left still in 5 minutes in order to get a 
sedimentation of the resin 
 Excess water was removed by vacuum, but there was left enough water to cover the 
top of the resin  
 The glass column was loaded with filtrated saturated sodium chloride solution 1.0 ml 
× 3, and thereafter flushed with 1.0 ml × 3 distilled water. Finally the glass column 
was dried by vacuum for 5 minutes. 
 
Separation of liposomal bendamustin from external bendamustin by ion-exchange 
chromatography 
 100 µl of the loaded liposome dispersion was added drop wise to the column followed 
by vacuum suction.  
 The column was flushed five times with 250 µl of distilled water under continuous 
vacuum suction. 
 The eluate, containing liposomal bendamustin, was collected in a flask, while the 







6.3 Encapsulation efficiency of bendamustin 
 
Encapsulation efficiency for both bendamustin- liposome formulation 1 as well as the new 
bendamustin- liposome formulation 2 was determined according to section 5.5.2.  
 
The respective liposome formulations were prepared according to section 5.4.2.1 and 5.4.2.2. 
The two formulations differed only in the composition of the bendamustin-solution used for 
direct loading of the VPGs. For bendamustin-liposome formulation 1 Ribomustin® was 
dissolved in water and diluted with 0.9 % sodium chloride solution to yield in a pH of 3.0. 
Whilst for the new bendamustin-liposome formulation 2 Ribomustin® was dissolved in water 
and diluted with PBS pH 2.0. (The concentration of bendamustin in both of the solution was 
the same; 9.09 mg/ml) Both of the loaded VPG-formualtions were re-dispersed in 0.9 % 
sodium chloride solution, yielding in a pH of about 4.5 for the outer aqueous phase of the 
liposome dispersions. 
 
Encapsulation efficiency of bendamustin- liposome formulation 1 
As shown in table 12, the encapsulation efficiency of bendamustin-liposome formulation 1 
was 44 ± 3.2 %.  
  
Table 12: Encapsulation efficiency of bendamustin-liposome formulation 1  
Parallels EE % (mean of triplicates ± SD) 
VPG 1 42 ± 1.6 
VPG 2 48 ± 3.9 
VPG 3 43 ± 1.9 
Mean VPGs and SD 44 ± 3.2  
 
The encapsulation efficiency found corresponds to a previous finding by Cicko, where the EE 
was determined to 41.5% ± 4.1 % [27]. 
 
The EE is quite high comparing to many other liposome formulations. One reason for this is 
that the formulation prepared is using a vesicular phospholipid gel as intermediate. VPGs 
contain greater lipid content than conventional liposomes, resulting in more liposomes per 
unit volume, and hence an increased ratio of the aqueous part entrapped within liposomes as 
compared to the total volume [24]. This in turn will result in high EE. 
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Furthermore, a certain amphiphilic characteristic of bendamustin will probably besides 
entrapment of drug within the aqueous core as well leads to some interaction with the lipid 
membrane. This might also add to the high EE of the drug. 
 
Encapsulation efficiency of the new bendamustin- liposome formulation 2 
As seen from table 13 the new bendmustin-liposome formulation 2 showed a EE of 61 %. 
This was an increase from the previous formulation by about 20 %.  
 
Table 13: Encapsulation efficiency for the new bendamustin-liposome 
formulation 2 
Parallels EE % (mean of triplicates ± SD) 
VPG 1 60 ± 3.3 
VPG 2 63 ± 0.5 
VPG 3 59 ± 3.5 
Mean VPGs and SD 61 ± 2.4 
 
For VPGs the EE of hydrophilic compounds is determined by the ratio of vesicle core volume 
as compared to overall aqueous volume in the VPG at the time of VPG formation.  
The theoretical maximum EE can be predicted if the phospholipid concentration, the vesicle 
diameter and the aqueous volume are known[24]. For VPGs consisting mainly of small 
unilamellar vesicles with a phospholipid concentration of 400 mg/g, which is the case for the 
bendamustin-liposomes, the maximum EE should be about 40 % [24]. However, experimental 
values may deviate from theory. It is difficult to achieve experimentally the theoretically 
predicted maximum encapsulation efficiency and true SUVs since vesicle size and lamellarity 
often are quite inhomogeneous. EE will also vary with type of drug and lipid used. Previous 
studies for the hydrophilic marker calcein encapsulated into SUVs with a phospholipid 
concentration of 400 mg/g, showed an EE of about 30-40 %  [24].  Considering this an EE of 
60 % for bendamustin within the new liposome formulation is quite high. 
 
The new bendamustin-liposome formulation 2 did only differ from bendamustin- liposome-
formulation 1 by a decreased pH within the aqueous core. The type of lipid, ratio lipid 
concentration /aqueous medium, as well as preparation technique was the same. Moreover, as 
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shown in section 6.1 both of the formulations showed to have the same size and size-
distribution. Hence, the increase in EE was most probably not a question of vesicle size.  
 
An explanation for the increased EE could be that there occurs some active loading of 
bendamustin during re-dispersion of the VPG. The zwitterionic molecules in the outer 
aqueous phase might diffuse through the lipid membrane, and when they reach the buffered 
pH of 2.0 inside the liposome, the molecules get protonated and are retained. 
 
For further investigation of active loading see section 6.7 
 
6.4 Degradation of bendamustin during speed-mixing. 
 
Degradation of bendamustin during preparation of the VPGs by speed-mixing was 
investigated for both bendamustin-liposome formulation 1 and the new bendamustin-liposome 
formulation-2 according to section 5.5.3.  
 
The results presented in table 14 and 15, showed a low degradation of bendamustin during 
speed-mixing for both of the formulations; 93.7% ± 4.1 intact bendamustin for bendamustin-
liposome formulation 1 and 97.5 % ± 2.2  intact bendamustin for bendmustin- liposome 
formulation 2 were left immediately  after preparation of the VPGs. In addition, the 
preparation seemed to give reproducible results regarding degradation of the compound; 
rather low standard deviations < 5 %. Moreover, the difference observed in amount intact 












Table 14: Intact bendamustin after speed-mixing of bendamustin-VPG formulation 1 
Parallels Intact bendamustin % (mean of triplicates 
and SD) 
VPG 1 90.8  ± 1.3 
VPG 2 98.5  ± 5.3 
VPG 3 92.0  ± 1.5 
Mean of parallels and SD  93.7 ± 4.1 
 
 
Table 15: Intact bendamustin after speed-mixing of bendamustin-liposome formulation 2.  
Parallels Intact bendamustin % (mean of triplicates 
and SD) 
VPG 1 96.3 ± 0.8 
VPG 2 100.0 ± 0.7 
VPG 3 96.3 ± 1.0 
Mean of parallels and SD  97.5 ± 2.2 
 
The results confirm that there is minimal degradation of bendamustin during speed-mixing. 
Thus, dual asymmetric centrifugation is a suitable technique for liposome preparation of the 
highly sensitive compound bendamustin.  
 
6.5 Efflux experiments  
 
Stability of bendamustin-solution at pH 7.4 
In order to check whether it makes sense to run efflux experiments in PBS pH 7.4, stability of 
bendamustin upon incubation in PBS pH 7.4 at 23˚C and 37˚C was investigated    according 
to section 5.5.4 
 
As shown in figure 20 bendamustin was quite unstable in PBS pH 7.4; half life was observed 
after about 10 minutes at 37 ˚C and 15 minutes at 23 ˚C/ room temperature. 
 
The retention time of bendamustin during HPLC measurement gave a small time- gap 
between injection onto the HPLC and until the samples were measured on the HPLC- UV 
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detector. This could be a reason for the relatively high standard deviations between the 
triplicates; 5-10 %. 
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Figure 20: Remaining intact bendamustin upon incubation in PBS pH 7.4 at 37 ºC and 23 ºC 
over time. 
 
Normally, hydrolysis of bendamtustin follows first order kinetics [15]. The reason why this is 
not seen here is unclear. The rapid degradation of bendamustin observed was probably due to 
pH. PBS does not contain any strong nucleophiles which might degrade bendamustin. At high 
pHs > 6, the bendamustin is expected to exist mainly in its anionic form, resulting in 
increased hydrolysis and hence in inactivation of the drug. This seems to be in accordance 
with a study done by Von G. Hesse which found that there was a fast hydrolytic cleavage of 







6.5.1 Efflux kinetics of bendamustin-liposome formulation 1 upon incubation in 
sodium chloride solution. 
 
Upon incubation of a bendamustin-VPG in physiological pH; 7.4, there will exist a situation 
were the pH inside and outside the liposomes are different resulting in unequal degradation 
rate of the drug in the two compartments. The bendamustin-solution used for preparation of 
the bendamustin-VPG formulation 1 was measured to reveal a pH of 3.0. Hence, this was 
probably the pH within the aqueous core of the liposomes. Upon re-dispersion and incubation 
in PBS pH 7.4 the external bendamustin in the outer aqueous phase will subsequently be 
degraded much faster than for the incorporated drug due to a higher pH. Because of the 
unstable system with references containing both liposomal and external bendamusin, it was 
difficult to investigate efflux kinetics alone. Therefore, it did not make sense to determine the 
overall content of bendamustin over time.  
 
In order to overcome this problem, and to know only the efflux of  drug out of the liposomes 
per time, a more stable system was chosen; where the drug is rather stable both inside as well 
as outside the liposomes within the respective time period measured. For this, 0.9 % sodium 
chloride solution was used as the outer aqueous phase, which corresponds to a pH value in the 
outer aqueous phase of about 4.5. This pH reveals a minimal degradation of bendamustin over 
the time-period the experiment lasted [15]. 
 
Efflux of liposomal bendamustin was carried out after the general describtion in section 5.5.5. 
Bendamustin solution pH 3.0 was directly loaded into liposomes resulting in bendamustin-
VPG formulation 1 as described in section 5.5.4.1. The VPG was re-dispersed with 0.9 % 
sodium chloride in ratio 1:3 yielding in a pH of 4.5 in the outer aqueous phase. The liposome 
dispersion was incubated at 37 ºC for the following time-points: 0, 10, 20, 30, 40, 60, 90 and 
120 minutes. At the respective time-points amount entapped/unentrapped liposomal 








The result presented in figure 21 showed no efflux within the time period measured.   
 






















Figure 21: Remaining intact bendamustin within bendamustin-liposome formulation 1 upon 
re-dispersion in 0.9 % Sodium Chloride Solution and incubation at 37 ºC over time. The 
liposome interior revealed a pH of 3 whilst the liposome exterior yielded in a pH of about 4.5. 
 
A possible explanation why there is not obeserved efflux in this system could be due to the 
difference in pH inside and outside the liposomes. Bendamustin has two pKa values; 4.5 and 
6.3. Above pH 4.5 the carboxylic acid group on the molecule is deprotonated and reveals a 
minus charge. Below pH 6.3 the amino group(s) are protonated resulting in positively charged 
molecules. Molecules with a net charge are restricted from diffusion over lipid membranes 
[36]. Bendamustin exists in a charged form in the whole pH range. However, between pH 4.5 
and pH 6.3 bendamustin is in a zwitterionic form. In this form there might act ionic forces 
between the carboxylic group and the amino group on the molecule, resulting in a ring 
formation. (Figure 22) This formation might act like a sterical shielding of the charges and 
give rise to an increased lipophilicity of the molecules, which in turn might result in a more 





Fig 22: Possible ring formation of the bendamustin molecule in the zwitterionic form.  
 
The difference in pH outside and inside the liposomes, will lead to a different total percentage 
of zwitterionic molecules in the two compartments. The bendamustin solution in the aqueous 
core was measured to have a pH of about 3. After re-dispersion of the VPG with sodium 
chloride solution in the ratio of 1:3, the pH in the outer aqueous phase was measured to be 
about 4.5. According to Hendelson-Hasselbach equation the percentage of cationic (amino-
protonated) bendamustin inside the liposomes at pH 3 is 97 %, which means that 3 % of the 
molecules exist in the zwitterionic form at this pH. In the outer aqueous phase, however, the 
pH is about 4.5, resulting in a concentration of zwitterionic molecules of 50 %. Although the 
volume- ratio of the aqueous core and the outer aqueous phase in the liposome-dispersion is 
about 1:8, the number of zwitterionic molecules per volume is higher in the outer aqueous 
phase than in the aqueous core of the liposomes.  
 
Under the assumption that both the cationic and anionic forms are not readily permeable 
whereas the zwitterionic form is permeable, such a pH gradient (pH 3 inside and pH 4.5 
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outside) is regarded to a situation where a gradient of the zwitterionic form occurs eventually 
leading to a net efflux of bendamustin from the outer to the inner aqueous volume. However, 
if this is the case, then there should be an increase in incorporated amount bendamustin over 
time. This was not seen in the results. An explanation for this might be due to a change in the 
pH gradient over time because of no buffer system. When some of the zwitterionic molecules 
have diffused into the liposomes, the pH in the liposome interior might be increased, resulting 
in loss of the pH gradient, and equilibrium between the liposome interior and exterior occurs.   
 
Another possible explanation to this might be that there is equilibrium between the ring form 
and the “normal” zwitterionic bendamustin molecules, leading to a difference in diffusion rate 
for the two forms over the membrane. Consequently, not all of the zwitterionic molecules 
may penetrate the membrane at equal speed. 
 
6.5.2 Efflux of bendamustin-liposome formulation 1 upon incubation in PBS pH  
2.0 
 
In order to investigate whether the theory of back-diffusion of zwitterionic bendamustin into 
the liposomes, explained under section 6.5.1, is correct, the same efflux experiment was 
repeated except that sodium chloride solution as re-dispersion medium was replaced by PBS 
pH 2.0. According to the theory, this experiment should give a rapid efflux of bendamustin 
out of the liposomes, because a pH of 2.0 in the outer aqueous phase would lead to a decrease 
in zwitterionic bendamustin molecules able to diffuse back into the lipsomes.  
 
The results presented in figure 23 show a drastically efflux in the system; 40 % of the 
encapsulated bendamustin had leaked out after approximately 15 minutes. The curve shows 
an exponential fit with most leakage within the first ten minutes. However, after about 20 
minutes the curve seems to reach equilibrium, and there is no further efflux observed after this 
time- point.  
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Figure 23: Remaining intact bendamustin within the bendamustin-liposome formulation 1 
upon re-dispersion in PBS pH 2.0 and incubation at 37 ºC over time. The pH in the liposome 
interior reveals a pH of about 3.0, whilst the outer aqueous phase reveals a pH of 2.0.  
 
An explanation why the curve is flattening off could be equilibrium of zwitterionic molecules 
between the inner and the outer aqueous phase. This might occur because the presence of 
hydrochloride ions from the Ribomustin® powder is making the solution more acidic inside 
the liposomes after some of the zwitterionic bendamustin has diffused out, resulting in loss of 
the pH gradient.  
 
6.5.3 Efflux kinetics of bendamustin-liposome formulation 1 in comparison to 
bendamustin-liposome formulation 2 upon incubation in PBS pH 7.4 
 
The findings in the efflux experiments above showed that the zwitterionic form of 
bendamustin tended to penetrate the lipidmembrane more readily than the cationic and 
anionic form. This in addition to the unstability of bendamustin at higher pH indicated that the 
optimal pH considering efflux and stability seems to be a further reduction of pH within the 
liposomes. By decreasing the pH in the aqueous core from 3 to 2, and holding the pH stable 
by adding a buffer system, will theoretically give a ten time reduction of zwitterionic 
molecules able to pass the lipid membrane.  Hence, the efflux should be decreased. The new 
bendamustin-liposome formulation was prepared according to section 5.4.2.2. 
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As observed from the efflux experiments in section 6.5.1 and 6.5.2, efflux kinetics of 
liposomal bendamustin would partly rely upon the incubation medium used. And as already 
mentioned, incubation of the liposome dispersion in physiological pH of 7.4, will lead to a 
rapid degradation of external bendamustin, thus making it difficult to determine the overall 
bendamustin- content over time. The overall content bendamustin show the stability of 
bendamustin in the liposome- dispersion over time. Therefore, upon incubation of the 
bendamustin liposomes in PBS pH 7.4, only the overall bendamustin content at time- point 0 
minutes can be used for calculation of the EE according to equation 2 under section 5.5.2. 
However, due to slow hydrolysis of bendamustin in low pH one could assume that possible 
decrease of liposomal bendamustin would be a result of efflux and not degradation. 
Subsequently, the efflux kinetics of bendamustin-lipsosome formulation 2 could be compared 
to the new bendamustin-liposomeformulation 2 upon incubation at physiological pH 7.4.  
 
Bendamustin-liposome formulation 1 and 2 were prepared according to section 5.4.2.1 and 
5.4.2.2. Both the VPGs were re-dispersed in the ratio of 1:3 with PBS pH 7.4 and incubated at 
37 ºC over time before efflux was determined according to section 5.5.5.  
 
Figure 24 shows the efflux kinetics of the two bendamustin-liposome formulations. For 
bendamustin-liposome formulation 1 half life of liposomal bendamustin was observed after 
90 minutes, whilst the half life of formulation 2 was observed after 180 minutes. However, 
because of the higher EE of formulation 2, the amount intact bendamustin within the 
liposomes over time is considerable higher for formulation 2 than for formulation 1. After 3 
hours there is left 30 % intact liposomal bendamustin within formulation 2, whilst for 
liposome formulation 1  30 %  intact bendamustin is left after 1 hour.  
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Figure 24: Efflux kinetics of bendamustin-liposome formulation 1 and 2 upon incubation in 
PBS pH 7.4 at 37 ºC over time. 
 
For bendamutsin- liposome formulation 1 the efflux curve seems to flatten off after 90 
minutes, which corresponds to the theory behind the results in section 6.5.2; there is no buffer 
within the liposomes, leading to an unstable pH inside the liposomes. After some of the 
bendamustin has leaked out, the pH in the aqueous core might decrease resulting in 
equilibrium of zwitterionic molecules between the two compartments. Consequently, efflux is 
reduced.  
 
The result does not correspond to a previous finding by Cicko, where the half life of 
bendamustin in bendamustin liposome-formulation 1 was estimated to be about 18 minutes 
[27]. However, in this study, there was not given detailed descriptions of the methods used, 
which makes it difficult to ensure that the experiment was carried out in a similar way. i.e; no 
information is given about the composition of the PBS, its molarity and pH. In addition it 
seems like no parallels were carried out.  
 
The reason why there is efflux in this system and not in the case where the liposomes where 
incubated in sodium chloride solution pH 4.5, showed in section 6.5.1 might be due to pH. 
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When the VPG is incubated in PBS pH 7.4, there is a concentration of zwitterionic 
bendamustin in the outer aqueous phase of 9 %. This is a considerable smaller percentage 
than in the case when the VPG was incubated with sodium chloride solution pH 4.5. In 
addition, the fast degradation of bendamustin in pH 7.4 in the outer aqueous phase would 
probably yield in a shift in equilibrium, and only a few intact molecules are able to diffuse 
back into the liposomes.  
 
Considering the fact that a change in pH from 3 to 2 theoretically gives a ten time reduction in 
zwitterionic molecules, the reduction in efflux was not as high as expected. The reason for 
this is unclear. 
 
The two improved effects for the new bendamustin-liposome formulation; reduced efflux rate 
as well as an increased EE result in more intact bendamusin over time, thus making the new 
formuation improved. 
6.6 Stability experiments of the new bendamustin-liposome 
formulation 
 
6.6.1 Stability of bendamustin  
 
Stability of bendamustin relies partly upon pH [14]. In a previous study for a related 
compound; L-phenylalanine mustard, hydrolysis upon different pHs was executed. The result  
showed that hydrolysis increased with increasing pH [37].  As shown under section 6.5 
bendamustin was fast degraded in pH 7.4 due to hydrolysis of the chlorine bonds. The new 
bendamustin-VPG formulation 2 revealed a pH of 2.0. Even upon entrapment within 
liposomes at low pH, bendamusin will not be suitable for long term storage due to 
degradation. However, considering the fact that the liposome formulation might be intended 
as a bed side preparation, the stability of bendamustin in the new liposome formulation was 
checked upon storage in room temperature over a time period of 24 hours as described in 
section 5.5.6.1 
 
According to the European pharmacopeia, drugs should contain at least 90 % of the intact 
active ingredient when applied to a patient [38]. Following this standard will mean that the 
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liposomes have to be used within a time period where no more than 10 % bendamustin is 
degraded. 
 
As seen from figure 25, the degradation rate of bendamustin shows a linear fit (R2= 0.99), 
where 90 % intact bendamustin is left after about 20 hours. After 24 hours there is 87 % ± 2 
intact bendamustin left. 
 






















Figure 25: Remaining intact bendamustin in bendamustin-liposome formulation 2 upon 
incubation at room temperature/23 ºC over time. 
 
The result shows that the formulation has to be prepared and used within the same day. 
Degradation would probably be a bit slower if the liposomes are stored at 4 ºC. Anyhow, this 








6.6.2 Stability of lipid  
 
It is a well known fact that the reaction rate of hydrolysis of fatty acid chains is strongly 
dependent on pH and temperature. Extreme pH values; very acidic or alkali, as well as high 
temperatures result in a faster hydrolysis and degradation of the lipids [39]. 
 
Hydrolysis normally follows first order kinetics. In early stages of hydrolysis the structure of 
the liposomes are not affected. However, other characteristics such as permeability of the 
membrane are seriously altered. Small amounts of Lyso-PC might stabilise SUV because of 
their preferential distribution in the outer leaflet of the liposome. At advantage stages, 
however, the liposome integrity is disrupted because free fatty acid and lysolipid are 
detergent- like molecules and start to dissolve the membrane [39].  
 
Due to the low pH of 2.0 within the new bendamustin-liposome formulation 2, stability of 
lipid; phosphatidylcholine, was investigated over 24 hours. In order to investigate whether 
bendamustin could influence on the rate of hydrolysis of the lipid membrane, a reference of 
“empty” liposomes were also prepared within PBS pH 2.0. Both the bendamustin-liposome 
dispersion as well as the “empty”- liposome dispersion were incubated at room temperature 
and assayed on HPTLC after the same recipe according to section 5.5.6.2.  
 




Picture 3: HPTLC plates; The upper plate in the picture shows the “empty” liposome samples, 
whilst the lowest shows the bendamustin-liposomes. Lyso-PC is seen as the narrow bands at 
the bottom of the plates.  
 
The calibration series of Lyso-PC shown in figure 26 shows a good linear fit; R2 = 0.9949. 
 
Lyso- PC (Linear fit)




















Figure 26: Calibration line Lyso-phosphatidylcholine 
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Ideally, in order to achieve higher statistically insurance of the results, triplicates of the VPGs 
should have been assayed. This was not accomplished due to the fact that 4 time points were 
measured for both of the VPGs, causing no space for application of additional samples on the 
HPTLC plates. However, as seen from table 16 and 17 the duplicates show very similar 
results, and hence should give a good indication of the tendency of the rate of hydrolysis of 
PC within both the bendamustin-containing liposomes and the “empty” liposomes. 
 
The results presented as % lyso-PC over time are shown in table 16 and 17. The amount of 
Lyso-PC in the bendamustin-liposome formulation was about 9 % after 24 hours. For the 
reference, the “empty” liposomes, the amount Lyso-PC after 24 hours was about the half; 
4.4 %.  
 
Table 16: Percentage Lyso-PC in “empty” liposomes over time.  
Incubation-time 
hours 
Lyso PC % 
Replicate 1 
Lyso PC % 
Replicate 2 
0 0,00 0,00 
1 0,00 0,00 
2 1,01 1,04 
24 4,33 4,51 
 
 
Table 17: Percentage Lyso-PC in the new bendamustin- liposome 
 formulation over time 
Incubation-time 
hours 
Lyso PC % 
Replicate 1 
Lyso PC % 
Replicate 2 
0 0,00 0,00 
1 0,00 0,00 
2 1,23 1,20 
24 9,01 8,68 
 
Not surprisingly the amount of Lyso-PC deriving from the liposome formulation was rather 
high after 24 hours. This was most probably due to the low pH of 2.0 in the formulation, 
resulting in a rapid hydrolysis of the ester linkages of PC. 
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The bendamustin- liposomes showed a considerably higher amount of Lyso-PC than the 
“empty” liposomes after 24 hours. This indicates that bendamustin acts as an indirect or direct 
catalyst in the hydrolysis of the ester linkages of PC, and in that order contribute together with 
the low pH to the rapid degradation of the lipid-membrane.   
 
Theoretically, a rise in temperature during speed-mixing could result in a faster hydrolysis of 
the lipids. However, no Lyso-PC was detected after 0 minutes, which was the first time point 
assayed after re-dispersion of the VPGs. Fortunately; this showed that preparation of the 
liposomes by speed-mixing is not a problem regarding lipid stability of the formulation. Thus, 
DAC is suitable as a bed-side preparation technique for bendamustin-liposomes. 
 
It should be mentioned that the re-dispersion and incubation of the VPGs in PBS pH 2.0 
would theoretically result in increased hydrolytic attack from the outer aqueous phase due to a 
higher volume on the outside of the liposomes, than if the undiluted VPG had been kept for 
storage. Consequently, storage of the undiluted VPG at a lower temperature such as 4 ºC, 
would probably lead to a decreased amount of Lyso-PC. However, practical reasons such as 
volume sampling made it difficult to incubate the VPG it self. Anyhow, the trend would 
probably be the same. The results indicate that the bendamustin-liposome formulation should 
be prepared and used within the shortest time possible.  
 
6.6.3 Stability in cell culture medium. 
 
Stability of the new bendamustin-liposome formulation was compared to the free drug upon 
incubation in cell culture medium at 37 ºC over time, as described in section 5.5.6.3. 
Cell culture medium contains a various amount of proteins, amino-acids, inorganic salts and 
vitamins which all might affect the stability of the liposome formulation. As has become clear 
from several previous studies, addition of medium may have a profound effect of liposome 
stability [40].   
 
As presented in table 18 and figure 27 the half life of the bendamustin-liposomes in medium 
was observed after about 20 minutes. This was not considerably longer than for the free 
bendamustin-solution which showed a half-life after about 14 minutes (table 18 and figure 
28).   
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Table 18: Half-life of free bendamusin compared to the new bendamustin-liposome 
formulation 2, upon dilution in cell culture medium pH 7.6 and incubation at 37 ºC.  
Formulation  
 
t ½ bendamustin 
Free bendamustin solution 14 min 
Bendamustin- liposome formulation 2 20 min 
 
 
Stability of bendamustin solution 























Figure 27: Remaining intact bendamustin in PBS solution upon dilution in cell culture 
medium pH 7.6 and incubation at 37 ºC over time.  
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Stability of bendamustin-liposome-formulation 2 in 























Figure 28: Remaining intact liposomal bendamustin in the new bendamustin-liposome 
formulation upon re-dispersion in cell culture medium pH 7.6 and incubation at 37 ºC over 
time. 
 
Kinetics of liposome leakage does often follow a single exponential release profile, with most 
degradation within the first time period due to inactivation of external drug [41]. Even though 
this tendency is seen in figure 28, liposomal bendamustin was expected to have a prolonged 
release due to protection of the drug from the outer environment. However, as seen from the 
results the liposomal bendamustin was quickly degraded, indicating that the system is 
complex. 
 
The stability of bendamustin in the liposome formulation is drastically decreased from what 
was seen upon incubation in PBS pH 7.4, where the half life was estimated to about 3 hours 
(See section 6.5.3). It is well known that liposomal leakage of drug in medium and plasma is 
increased from non-biological fluids, though the reasons for this are not fully fulfilled. Hence, 
an explanation for the rapid degradation of liposomal bendamustin might be a more 
permeable liposome membrane, resulting in increased loss of drug.  However, stability, 
measured as the leakage rate, strongly depends upon the lipid composition. Presence of 
impurities, structural defects and rough surfaces are examples of factors making the surface 
easier to penetrate [41]. The lipid composition EPC3/CH used in the liposome formulation for 
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bendamustin is a well documented ideal mixture, shown to exhibit high mechanical stability 
for liposome preparations [41]. As mentioned in section 3.4 the presence of cholesterol 
increases the lateral packing in the liquid crystalline phase and eliminates phase boundaries in 
the fluid gel phase. In addition it maintains a smooth surface [41]. Thus, the lipid membrane 
in the bendamustin- liposomes should be quite stable. 
 
Moreover, the volume used for re-dispersion and incubation in this experiment compared to 
the “PBS experiment” was the double, resulting in a higher concentration gradient between 
the inner and the outer aqueous phase of the liposomes; ratio about 1:15. However, this is 
probably only partly the reasons for the extremely rapid efflux of liposomal bendamustin.  
 
The most obvious theory for the rapid degradation of liposomal bendamustin is the presence 
of proteins in the medium and opsonisation of the liposomes. Bendamustin is a strong plasma 
protein-binder; binding to the extent of 95 %, preferably to albumin[13]. Proteins, especially 
lipoproteins, might interact with the liposomes by simple charge-charge interactions and/or 
hydrophobic interactions, which in turn lead to protein adhesion or adsorption on the 
liposome surface or penetration into the liposome bilayer [41]. Bendamustin sitting in the 
lipid bilayer pointing out from the liposome surface, would be fast recognized and bound to 
the proteins in the medium. Proteins penetrating into the liposome bilayer might result in loss 
of both encapsulated and incorporated bendamustin in the membrane, as well as liposome 
disintegration might occur. 
  
It is worth to mention that cell culture medium might represents a more liposomicidal 
environment than blood because of higher activity of proteins in cell-free solutions [41]. But 
then again, other components in blood and RES might contribute to liposome disintegration. 
Therefore, one should always be careful with extrapolating the results of in vitro experiments 
to an in vivo situation where the conditions are even more variable and complex. Moreover, it 
might be worthy to test the liposome-formulation in cell- assays and furthermore in vivo, to 
see if the efficiacy as well as toxicity of the bendamustin-liposomes in comparison to the free 





6.7 Active loading of bendamustin 
 
The results presented in section 6.5 have indicated that bendamustin in its zwitterionic form 
might have an increased lipophilicity making it capable of diffusing through the liposome 
membrane more readily than both the cationic and anionic forms.  In that respect an active 
loading of bendamustin should be possible. 
 
Bendamustin takes predominantly a zwitterionic form in the pH range between pH 4.5 and 
6.3. The molecules in this pH-range are only sparingly soluble; calculated mass solubility in 
water at pH 4 = 0.86 g/L and at pH 6= 0.32 g/L [9]. This is of course a limitation, since active 
loading is dependent of concentration of drug in the outer aqueous phase. However, even with 
a low concentration of dissolved drug, the tendency of an active loading of drug should be 
seen if the zwitterionic molecules readily diffuse through the lipid membrane. At higher and 
lower pH, solubility increases (calculated mass solubility at pH 2.0 = 16 g/L and pH 8 = 9.3 
g/L) [9]. Considering the fact that bendamustin exist in a charged form at all pHs, the 
reduction in solubility of bendamustin between pH 4 and 6, support the theory described 
under section 6.5; the drug exhibit, in the zwitterionic form, an increased lipophilicity due to a 
ring formation of the drug. 
 
The active loading experiment was carried out according to section 5.4.3; “empty” VPGs with 
a high buffer-capacity pH 2.0 were prepared. The VPGs were subsequently re-dispersed with 
PBS solution pH 4.5 before bendamustin-solution was added drop-wise to the dispersion to 
hinder precipitation. The bendamustin would predominantly yield in a zwitterionic form in the 
outer aqueous phase, thus making it capable of diffusing into the liposome interior where it 
gets protonated due to the low pH, and in that order get retained.  
 









Table 19: Entrapped amount bendamustin, active loading experiment. 
Parallels EE% (Mean and SD of internal 
triplicates) 
VPG 1 14.5 ± 0.3 
VPG 2 12.7 ± 0.4 
VPG 3 14.2 ± 0.6 
Mean and SD 14 ± 1  
 
The EE of 14 % observed in this experiment was lower than seen for other active loading 
processes such as for Doxorubicin [42]. 
 
Even though the concentration of bendamustin added to the liposome dispersion is quite low, 
the number of zwitterionic molecules per volume is higher than within the aqueous core of 
loaded lipoosmes due to pH. In this respect an influx of drug from the outer aqueous phase to 
the “empty” liposome interior should be just as fast as the other way around. 
 
There will always be equilibrium of diffusion between the liposome interior and exterior. The 
net diffusion of drug is therefore dependent on a shift in equilibrium due to a concentration- 
and/or a pH gradient. In that respect one might assume that after a certain amount of 
bendamustin has diffused into the liposome interior, the buffer capacity could be exceeded 
and no longer sufficient. As a consequence the pH gradient is changed and the equilibrium of 
diffusion is shifted, resulting in no higher entrapped amount bendamustin within the 
liposomes.   
 
However, all the parameters which might be critical for an active loading process, such as the 
highest bendamustin concentration possible without any precipitation, optimal buffer 
capacity, loading time and temperature, are not fully investigated. Especially is an active 
loading process often time-dependent, and one might assume that the loading time in this 
experiment was too short, leading in a suboptimal active loading. Optimum of the critical 
parameters important for obtaining a successful loading should be executed. Unfortunately, 
lack of time made it impossible to further investigate this topic.What can be concluded from 
these findings, however, is that bendamustin in its zwitterionic form is capable of diffusing 
through the liposome membrane to a certain extent. 
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7 CONCLUSIONS 
The first step in this approach was to prepare bendamustin- liposomes by DAC according to a 
method developed by Cicko, and subsequently investigate leakage of drug out of the 
liposomes over time. The results from these experiments indicated that bendamustin in its 
zwitterionic form tended to diffuse through the liposome membrane more readily than both 
the cationic and anionic forms. This was assumed to be due to intra-molecular charge-charge 
interactions of bendamustin in its zwitterionic form, thus increasing its lipophilicity. 
Moreover, bendamustin showed to be unstable in its anionic form at pH; 7.4 due to 
hydrolysis.  
 
A new bendamustin liposome formulation was developed. For this liposomes were prepared 
in a PBS pH 2.0, which should decrease the content of zwitterionic molecules able to leak out 
of the liposome interior.  The new formulation showed an EE of 61 % ± 2.4, which was about 
20 % higher than for the old formulation. Furthermore, efflux of the new formulation was 
compared to the old upon incubation in 150 mM PBS pH 7.4 at 37 °C over time. The results 
showed a prolonged half life of 3 hours in comparison to 1.5 hours, respectively. Based on 
these two positive effects, the new formulation showed a threefold increase of intact 
liposomal bendamustin over time. 
 
Stability of the new formulation regarding degradation of bendamustin as well as lipids was 
investigated upon incubation at room temperature over 24 hours with subsequent assay on 
HPLC and HPTLC, respectively. 90 % intact bendamustin was left after about 20 hours, 
whilst a relatively fast hydrolysis of lipid was observed after 24 hours; 9 % lyso-PC. 
Bendamustin showed to increase the hydrolysis of phosphatidyl choline in the liposome 
membrane. This stated that the formulation should be prepared and used within the same day 
as a bed-side preparation. Unfortunately, upon incubation in cell culture medium at 37 °C, the 
liposomal bendamustin was quite rapidly degraded, and showed a minor increase in stability 
as compared to the free drug, t ½ ; 20 min and 14 min, respectively. This was assumed to be a 
result of opsonisation of the liposomes due to proteins in the medium, which in turn 
inactivated liposomal bendamustin. Finally, an attempt of an active loading for bendamustin 
was carried out by the means of a pH gradient between the liposome interior and exterior. 
Bendamustin was added to empty liposomes at a pH where the drug was in zwitterionic form, 
while the interior of the liposomes was acidic. An EE of 14 % was obtained. However, further 
investigation need to be done in order to see if optimization of the loading process is possible. 
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8 FUTURE PERSPECTIVES 
 
At present time, further investigations of the new bendamustin-liposome formulation in cell 
culture assays and in vivo might not be relevant. The reason for this is the quite fast 
degradation of liposomal- bendamustin in cell culture medium, most probably due to adhesion 
and/or adsorption by proteins in the serum. However, a possible further approach might be to 
protect the liposomes from opsonisation by the means of membrane modifications. An 
alternative for this is coating the liposomes with a polymer such as polyethylene glycol, which 
might protect the liposomes from being opsonised and recognized by cells of the reticulo 
endothelial system, thus prolonging the half life of drug in serum.  
 
Furthermore, it would be of interest to test if optimization of the active loading process of 
bendamustin is possible, giving a further increase in encapsulation efficiency of drug. For 
this, variations in the loading protocol such as concentration of bendamustin, optimal buffer-
capacity and time of incubation should be investigated. Generation of an ammonium sulphate 
transmembrane gradient to the system might give precipitation of bendamustin in the 
liposome interior, which in turn might reduce leakage of drug out of the liposomes. Such a 
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Calculation percentage ionised bendamustin. 
 
Henderson- Hasselbach equation: 
pH= pKa + log ([A¯]/[HA]) or pH= pKb + log ([B¯]/[BH]) 
 





% ionisation pH 3 (aqueous core): 
100/ (1+10^pKa-pH) = 100/ (1+10^ (4.5-3.0) = 3 % 
3 % of the COOH group of bendamustin in the aqueous core is protonated, while 97 % is 
deprotonated. 
 
100/ (1+10^pH-pKa) = 100/ (1+10^(3.0-6.3) = 99.95 % 
99.95 % of the NH2 groups of the bendamustin in the aqueous core are protonated,  
0.05 % is neutral. 
 














Approaches of optimization of Ion exchange chromatography- Cholesterol values  
 
Cholesterol values, first ion exchange method method used 
 











SD 10.7 or 3 % 
 
Cholesterol values in eluates. 
Parallels 
Eluates 
Cholesterol µg/ml Cholesterol recovery % 
1 210.0 59.1 
2 223.2 61.4 
3 255.7 71.5 
4 139.4 40.4 
5 139.7 39.0 
6 91.9 27.5 
Mean 176.7 49.8 
















SD ± 18.3 or 5 % 
 
Cholesterol values in eluates. 
Parallels Eluates  Cholesterol µg/ml Cholesterol recovery % 
1 281 79 
2 266 75 
3 218 61 
4 244 68 
5 300 84 
6 255 71 
7 300 84 
Mean 266 74 
















Cholesterol values references 











Cholesterol values in references  





SD ± 6.1 or 1.6 % 
 
 
 Cholesterol values in eluates  
Parallels Eluates 
(Flushed five times with  
250 µl distilled water) 
cholesterol µg/ml Cholesterol recovery % 
1 305 82 
2 316 85 
3 330 89 
4 317 85 
5 331 89 
Mean 320 86 
SD ± 9.7 or 3 % 3 
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